

JOINING JACK

England & Wales · Charity number 1148156

Details

Status Registered

Legal form Other

Registered 2012-07-17

Register [View on the Charity Commission register](#)

Contact

Address ADM Print
16 Appleton Street
Wigan
Lancashire
WN3 4BZ

Phone 07876860401

Email info@joiningjack.org

Website www.joiningjack.org

Activities

Objects: TO RELIEVE THE NEEDS OF SUFFERERS OF DUCHENNE MUSCULAR DYSTROPHY (DMD) BY FUNDING RESEARCH INTO METHODS OF TREATMENT AND CURE OF THE CONDITION.

Activities: The principal objective of the charity is to relieve the needs of sufferers of Duchenne Muscular Dystrophy (DMD) by funding research into the methods of treatment and cure of the condition.

Classification

- **How:** Makes Grants To Individuals, Makes Grants To Organisations, Provides Other Finance, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** The Advancement Of Health Or Saving Of Lives
- **Who:** Children/young People, People With Disabilities

Geography

- **Area of benefit:** NATIONAL
- Wigan

Finances

Period end	Income	Expenditure	Assets	Employees
2025-04-30	£889,652	£672,888	£1,840,367	3
2024-04-30	£504,269	£728,898	£1,653,229	3
2023-04-30	£173,883	£665,156	-	-
2022-04-30	£173,813	£759,816	-	-
2021-04-30	£187,167	£225,573	-	-

Trustees

Name	Role	Appointed
Andrea Kent		2014-05-16
Jonathan Whitworth		2014-05-16
Kristian Radlinski		2014-05-16

JOINING JACK

England & Wales - Charity number 1148156

Accounts

Charity registration number 1148156 (England and Wales)

JOINING JACK
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2025

JOINING JACK

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees	K Radlinski A Kent J Whitworth
Charity number (England and Wales)	1148156
Registered office	ADM Print 16 Appleton Street Wigan Lancashire WN3 4BZ
Auditor	Sumer Auditco Limited 1st Floor Waterside House Waterside Drive Wigan Lancashire WN3 5AZ

JOINING JACK

CONTENTS

	Page
Trustees' Report	1 - 12
Independent auditor's report	13 - 15
Statement of financial activities	16
Balance sheet	17
Statement of cash flows	18
Notes to the financial statements	19 - 27

JOINING JACK

TRUSTEES' REPORT

FOR THE YEAR ENDED 30 APRIL 2025

The trustees present their annual report and financial statements for the year ended 30 April 2025.

The financial statements have been prepared in accordance with the accounting policies set out in note 1 to the financial statements and comply with the charity's governing document, the Charities Act 2011, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)".

Objectives and activities for the public benefit

Charitable objectives are; to relieve the needs of sufferers of Duchenne Muscular Dystrophy (DMD), speed up treatments for all children and adults living with DMD by funding research into methods of treatment and a cure for the condition.

Our shared Scientific Advisory Board with Duchenne UK

Our Scientific Advisory Board (SAB) is a fundamental part of our project review process – and ensures our supporters' donations are being invested in the right projects to advance the DMD field. For several years now, we have been proud to work with the following experts:

Prof Giovanni Baranello
Dr John Bourke, Newcastle University, UK
Prof Dame Kay Davies, University of Oxford, UK
Prof Annemieke Aartsma-Rus, Leiden University Medical Centre, Netherlands
Prof Jordi Diaz Manera
Dr Tina Duong
Dr Dada Pisconti, Stonybrook University, USA
Dr Isabelle Richard
Dr Valeria Ricotti
Dr Carina Schey
Prof Francesco Saverio Tedesco
Dr Graeme Wilkinson

These are all researchers at the top of their field and are generous enough to share their expertise and knowledge, regardless of the huge demands on their time.

Achievements and performance

On 22 April 2016 Joining Jack joined forces with Duchenne UK, another parent-led charity formerly called The Duchenne Children's Trust, set up by Emily and Nick Crossley. Joining Jack remains a separate charity and holds stand-alone fundraising events but now shares a research strategy, scientific advisory board and Director of Research with Duchenne UK.

Research

An end of year Research Project Report, dated December 2025, from Mike Bond, Director of Research for Duchenne UK and Joining Jack, (Joining Jack x DUK - End of Year Report - Research 2025) provides a progress update on all the projects funded by Joining Jack in the Duchenne UK portfolio. This is an overview of new funding opportunities in the pipeline. The report covers active projects and projects that have completed in 2025. Historical projects which have closed in 2024 and before are not included. For each funded project, a status, update on progress and update on funding is included.

JOINING JACK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2025

Our research strategy has now expanded to include six key elements to it, all of which are integral to accelerating and advancing research. Funding the research is the first crucial step, but on its own it isn't enough. We need to look at the overall landscape of research and drug development, and our strategy has been developed to reflect this.

1. **Fund and accelerate research for early stage clinical trials:** Our approach is 100% focused on advancing research and getting treatments into clinic and to patients as quickly as possible. Working alongside co-founder of Duchenne UK Emily Crossley, our co-founder, Alex Johnson, actively seeks out projects and potential therapies which could benefit the current generation of patients. We run an international grant call. We invest globally in basic science, translational research and clinical trials.
2. **Facilitate and accelerate research:** We are committed to accelerating the pace of research, ensuring that we remove potential obstacles and roadblocks that lie in the path of drug development. It is vital that the research we fund has the potential to translate into clinical trials, and so we fund the doctors, nurses and physiotherapists necessary to conduct trials in the UK. We created and expanded the DMD Hub which has the ambition that every child born with Duchenne in the UK has the opportunity to take part in research. We also support and encourage national and international collaboration to allow researchers and clinicians to collaborate and progress research. We are proud to support the Treat-NMD network and their bi-annual TACT meetings to review potential clinical trials for Duchenne muscular dystrophy.
3. **Implementation of the Standards of Care (SoC) in the UK:** The updated SoC were published in The Lancet of Neurology in 2018. They are ambitious and significantly advance on the 2010 version. While this is welcomed by families and clinicians, it presents challenges at a national level where the health care systems need to increase or change provision, and in many cases increase resources in order to deliver the fully updated SoC. We will continue to deliver the project to ensure everyone in the UK living with Duchenne has access to the best care.
4. **Work alongside industry:** We work with industry, advising on clinical trial designs. We have advised on the protocols of a number of different trials. We work with Project Hercules and their industry partners to help collect the data they need to aid reimbursement decisions of drugs.
5. **Continued engagement with regulators and policy makers:** We are engaging with policy makers and regulators on many issues, from campaigning for Early Access to Medicines to engaging with the Health Technology Appraisal system.
6. **Collaborate with families and charities globally:** We work with families to empower them to get the best access to care and treatments for their children. Working alongside Duchenne UK, we will continue to deliver the New Horizons Duchenne patient conference – more than 300 are expected to attend 6 and 7 February 2026.

Volunteers

The charity has an incredible ever-growing army of volunteers who enable the staging of our flagship fundraising multi-participant events. An existing database of more than 150 names alongside local running and cycling clubs and Army Cadets, are called upon to help with pre-event preparation (goodie bag packing and race/ride packs) and on the day to hand out medals, water, refreshments marshal routes and support runners/riders at the start and finish. Our volunteer database continues to grow help us create and stage the four mass participation events.

JOINING JACK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2025

Achievements and performance

Fundraising activities and events

Run Wigan Festival

2017 saw us launch two new flagship fundraising events the first of which was the Run Wigan Festival in March featuring a Half Marathon, a 5k and Family Mile run. The event celebrated its third year in 2019 when a fourth distance was introduced to the event in the shape of a 10 Miler.

The 4th Run Wigan Festival in 2020, was cancelled with less than a week to go, due to COVID and eventually staged virtually and with a date never officially set for the 2021 event due to the ongoing restrictions and a third national Lockdown, we were unable to stage the event for two years.

The Run Wigan Festival returned in 2022 and included 329 deferred entries from 2020, while all runners who had taken part in the Virtual Run Wigan Festival of 2020 were offered a 25% discount as a gesture for their support throughout the ongoing cancellations. This also helped to maintain engagement with the charity's established event network. Deferrals and discounts did have an effect on fundraising and mean the event could have potentially run at a loss but the Trustees, along with the co-founders, and Race Director, were in agreement that it was important to stage the event to maintain the charity and the event's reputation. It would be the final event to be affected financially as a knock-on effect of COVID and Lockdowns. Thankfully, it turned around a profit of £10,000.

The Run Wigan Festival moved to a new home in 2023 following in the footsteps of the Wigan 10k and relocating to Mesnes Park. This involved a few tweaks to the routes and a bigger section of the flagship HM race taking place along the canal requiring increased volunteer and steward numbers. The relocation and route tweak proved a success and provided promising signs for us to build on, as we continue to navigate out of the devastation caused to mass participation events as a result of COVID's legacy. £13,000 was raised, a slight increase on 2022.

In 2023 and 2024 the Run Wigan Festival continued to grow as runners supported the natural pattern of a return to mass participation events, somewhat slower but nevertheless predicted, and in 2025 the Run Wigan Festival remained at Mesnes Park and, building on the green shoots from the 2023s event, numbers continued to rise. The event proved to be our biggest March flagship fundraiser since 2018!

2025 NUMBERS:

1,500 HM

1,000 5k

320 FM (& 180 on day)

TOTAL: 3,000

The event raised £33,000 - a 10% increase on 2024.

The date for the 2026 Run Wigan Festival has been set for Sunday, March 15, and we are delighted to report that numbers are keeping track with 2025 for the HM and are up on the 2025 5k at this point in the registration process. We are hopeful of equalling and perhaps even bettering last year's totals in both numbers and fundraising. We have lost one associate sponsor and gained a transport partner.

JOINING JACK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2025

Wigan 10k

Due to the ongoing works in the town centre, the decision was taken to relocate our inaugural flagship fundraising event the Wigan 10k (first staged in 2013), to Mesnes Park in 2022 when we invited vendors to provide food and drink options for runners. There was also a return to live entertainment following the race – the first time since COVID.

Final numbers were disappointing which we believe, having spoken to our Event Partners and other Race organisers, is an ongoing consequence of COVID, and the cost of living crisis. However, the new Start/Finish, along with food and drink vendors at Event HQ proved to be an overwhelming success.

Since the disappointing numbers of 2022, the event now seems to have turned a corner and numbers have been on the up. 2023 saw us sell out at 1,900 runners in the 10k race raising £35,000. 2024 also saw us sell out at 2,900 runners, raising £50,000. And last year's event made further huge strides, with 3,122 (26 on the day) runners – our highest total since 2017.

2025 NUMBERS:

3,096 10k (& 26 on day)

424 Family Mile (& 130 on day)

TOTAL: 3,676

The 2025 event raised a fantastic £55,000 - another 10% increase on the previous year. It is a continually encouraging picture for our events-based fundraising and we hope to continue that trend with further increases in 2026.

In 2025, our original flagship fundraising event also passed the amazing milestone of having raised £1/2million for Joining Jack, as well as thousands of pounds for so many other charities, groups and organisations.

The date for the 2026 Wigan 10k has been set for Sunday, September 6th. Given the promising numbers that took part in 2025, we have once again targeted 3,000 runners taking us closer to totals achieved pre-pandemic. The encouraging news is that we are already well on our way with more 500 runners signed up with more than 200 days to go!

JOINING JACK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2025

Fundraising 2025 Summary

The charity relies heavily on our own flagship events and supporters taking part in mass participation events. Many if not all of these were cancelled in 2020 and in the first half of 2021 due to COVID-19 Coronavirus. This had a significant effect on the charity's income both in 2020 and 2021 and has also affected overall fundraising income in 2022 with a continued knock-on effect of deferrals and discounted entries in the Run Wigan Festival 2022, our first event of the year.

With the cost of living crisis also having an effect on numbers taking part, the overall fundraising total for 2022 was around 25% of what the charity has previously raised. However, 2023 looked to be an indication of a significant turning point for events and fundraising and 2024 and 2025 has certainly continued that trend. The return to higher numbers taking part saw our biggest events since 2017 in both March and September. We hope to continue that in 2026 to get back to somewhere close to the record numbers.

In 2025, the combined total fundraising from the two flagship running events totalled £88,000.

Other fundraising and awareness initiatives and campaigns, community work & recognition

- The charity was supported by a number of events ranging from being chosen as beneficial charity form the 5th birthday celebrations at a local e-bike centre MiRider, to a charity Golf Day for Team JJ from our friends at Develop UK.

We also met the lovely James Hooton who had lost his son to Duchenne over 20 years ago and made a donation in memory of his son and wife.

The marvellous Michelle Beckett whose son Ryan was another Duchenne warrior, continued to raise some fantastic funds for Joining Jack while Sarah Grannell led a group on a 10k hike in Yorkshire whole fundraising.

And we said farewell to Rita Skett at the Wigan 10k, who hung her trainers after taking part I every race since the first race in 2013 and raised hundreds of pounds.

- Alongside our partner Charity Duchenne UK, we were part of the annual New Horizons team, the second two-day conference, in March 2025. The conference brought together people from all across our community. At it we met the parents of children who have recently been diagnosed with DMD, as well as people we have forged a friendship for over a decade as a result of sharing our rare reality.
- Jack has completed his first year in college, passed his Driving Theory test and has applied to University, to continue his education in graphic design. He has also completed further work experience with Wigan Warriors. He also increased his extra-curricular sporting achievement promoting the Powerchair Hockey league and he has been a star in the FA Cup in Powerchair Football, travelling across the country to compete.

JOINING JACK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2025

ACCESS TO TREATMENT (Givinostat)

Jack has also been at the forefront of the charity's campaign work to secure access to treatments for ALL boys with Duchenne, in particular the Time Is Muscle campaign.

The Duchenne community continued the fight for access to givinostat throughout 2025 with Jack and Eli from Duchenne UK at the forefront of the campaign. Givinostat was given approval by the MHRA for all people with Duchenne aged six or older in December 2024.

It was another huge milestone for the Duchenne community and something very close to Jack's heart after he had already taken part in two tough clinical trials before starting the treatment for givinostat at the age of 12, an age at which boys with Duchenne typically can stop walking.

Over the past 12 months, working alongside partners and the national patient charity Duchenne UK, we have held two drop-in events in Parliament, met with more than 35 MPs and peers, and successfully influenced 19 NHS Trusts on access.

Accelerating access to treatment has always been at the heart of our mission to end Duchenne. At the start of 2025, despite MHRA approval and givinostat being available FREE through the Early Access Programme (EAP), no patients were receiving it. The Time is Muscle campaign changed that. By the end of this year, 20 of 24 NHS Trusts had started treatment for more than 200 patients, with more preparing to roll out following NICE approval. Working alongside NICE, we secured full NHS funding for all eligible patients in December 2025, ensuring long-term access to this important therapy.

Strong cross-party support in Parliament, with MPs challenging the postcode lottery of access, kept pressure on the government to act. At the same time, we worked Trust by Trust to secure delivery of the EAP, backed by national and local media coverage exposing the injustice families faced – something Jack took on personally, he wanted his friends to be given the same chance he had. This growing momentum drove change.

The success of our campaign was powered by the strength of our entire Duchenne community. Families, friends, and supporters came together, engaging political representatives, speaking to the media, and bravely sharing their stories, to turn advocacy into action and drive real change for everyone affected by Duchenne.

In November 2025, NICE issued draft guidance approving givinostat, requiring all remaining Trusts to make it available within three months under the NHS Constitution, a major victory for families.

200 patients and more each day are now receiving givinostat, the first treatment shown to slow down progression of DMD in clinical trials and closed 2025 with two approved treatments, givinostat and vamorolone, bringing new hope to families affected by Duchenne.

DMD CARE

DMD Care UK's therapy working group launched two new guidance documents – one for healthcare teams and one for people with DMD and their families which give information about the best standards of physiotherapy and occupational therapy care needed at different stages of the disease.

On World Duchenne Awareness Day in September, the National Institute for Health and Care Excellence (NICE) recognised DMD Care UK's guidelines for cardiac care and found them to be 'a useful resource that will help clinicians improve care.'

In November we received a lovely letter from Andy Burnham, Mayor of Greater Manchester congratulating Alex and Andy and Joining Jack for the NICE recognition of the DMD Care UK Cardiac Care guideline which he described as 'a landmark moment for the Duchenne community'.

JOINING JACK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2025

INVESTMENT FOR THE FUTURE (Virtual Hospitals)

We are proud to be driving a bold new approach to healthcare for adults living with Duchenne by funding a pioneering virtual care model that brings hospital-level support into people's homes. This initiative responds directly to the growing needs of the adult Duchenne community. As more men live longer with Duchenne, their care becomes more complex. Yet adult services are often less coordinated and under greater pressure than paediatric care, leading to poorer outcomes and lower satisfaction.

Impact

Our battle against Duchenne muscular dystrophy is heading into its 14th year. We have included an update on how the work alongside our partners the national patient charity Duchenne UK, is making significant progress in many areas:

- The approval of Vamorolone by the FDA and EMA. This is the first drug for all people with DMD, which Duchenne UK played a key role in developing.
- While our Project HERCULES is helping support the health technology assessment of Vamorolone, which is currently being appraised by NICE.
- We launched a new project to drive better care for nutrition and weight management in DMD.
- The third version of our SMART Suit prototype has been developed and is being tested.
- Our psychosocial programme has developed a referral pathway for children with DMD
- Our DMDhome digital platform has entered the validation phase. DMDhome uses video capture and computer vision analysis to measure limb function in DMD. The study will aim to validate this new approach for use in clinical trials and potentially in the approval of new medicines for DMD.
- Our Central Recruitment Database has moved on from the pilot stage. Every commercial DMD trial opened in the UK since its establishment has recruited patients using it.
- We are undertaking extensive research with young people with DMD to completely rethink how wheelchairs can help them live their lives.

Elevox update

Elevox is a new arm-support device we are developing for people with Duchenne. It's made to be used while sitting in a wheelchair and helps users move their arms more easily as their muscles get weaker. Many people with Duchenne say losing arm movement is harder than losing the ability to walk, because we use our arms for many daily tasks like eating, drinking, and talking.

- Elevox works by boosting the user's remaining muscle strength. It makes the arm feel lighter, like moving in water, so tasks feel easier and more natural.
- In 2025, we focused on improving the mechanical design and making sure the controls feel smooth and natural. We worked with experts at the University of Central Lancashire to study how people move their arms during important tasks. This helped us design a lift system that balances the arm's weight.
- We started with a shoulder support prototype, since the shoulder is a complex joint. We also created a comfortable vest to hold the device. Later, we teamed up again with engineers at Frazer Nash Consultancy to build a lower arm support with a special elbow joint. By the end of the year, we had a full-size prototype that can be tested next to any wheelchair.
- Testing with people in the Duchenne community has been key. Their feedback helped us improve the design and plan the next steps. In 2026, we'll focus on final testing, getting medical approvals, and preparing for production. We hope to launch Elevox in early 2027 to help people with Duchenne stay independent.

JOINING JACK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2025

Funding and research projects to date

We have listed in the table below a list of the grants we have awarded to date. We have colour-coded the grants to show how we are supporting the whole therapeutic development pipeline. Joining Jack is committed to ensuring that as much as possible of our funds goes to developing research into a treatment or a cure for Duchenne Muscular Dystrophy. We are particularly focused on transitional research, research that takes potential therapeutics out of laboratories and into clinical trials. Working closely with our partner charity Duchenne UK, our trusted team of scientific advisors, patient advisory board and trustees, we have made major decisions on how to spend the funds raised. The grants that we have awarded have led to breakthroughs that are changing the therapeutic landscape for the Duchenne community.

DMD Care UK = Red
Basic Research = Yellow
Preclinical Research = Green
Clinical Trial Support = Blue
Clinical Trials = Orange

Project Name	Research/Institution or Company	Project Status	Total Grant Award
Virtual Hospitals	Queen Square Institute of Neurology, London	Ongoing	£441,219
DMD Care Transition	Leeds Teaching Hospital	Ongoing	£200,000
Smart Suit Project	Spinal Muscular Atrophy UK (SMA UK) & University of Liverpool	Ongoing	£150,000
DMD Care Phase 2	Newcastle University	Ongoing	£150,000
DMD Hub research Fellow/ Clinical Trial Support	Dr Anne-Marie Childs, Leeds Children's Hospital	Ongoing	£35,000
Home-based video assessment of DMD	Aparito	Ongoing	£173,336
DMD Care Neuropsychiatrist	University of Glasgow	Complete	£75,000
Antifibrotic/antiadipogenic drug Fibrogenesis	Newcastle University	Complete	£32,688
Hydrotherapy Clinical Trial	Dr De Geode, Royal Preston Hospital	Started	£118,000
Immunology Grant Call Award	Professor Kanneboyina Nagaraju at Binghamton, the State University of New York	Started	£1,000
Biomarker Trial	Duke University	Started	£20,000
Dream Chair development	Whizz Kidz	Ongoing	£50,000
DMD Care UK	Newcastle University	Ongoing	£140,000
Immunology Grant	University of Florida	Ongoing	£185,000
Splint Trial	Newcastle University	Started	£10,000
Stem Cells	University of Minnesota	Started	£140,000
Vitamin B3	Leiden University	Started	£10,000
Tackling fibrosis and muscle regeneration	Agada Biosciences	Started	£25,000
Repurposing Drugs	Dr Olivier Dorchies, University of Geneva	Started	£25,000
Testosterone extension	Prof Volker Straub, University of Newcastle	Started	£10,000
Adult NMCCC	Dr Chiara Marini-Bettolo, University of Newcastle	Ongoing	£10,000

JOINING JACK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2025

Project Name	Research/Institution or Company	Project Status	Total Grant Award
Open label extension study for Tamoxifen	Dr Dirk Fischer, University Children's Hospital Basel	Pending	£230,000
Taurine	Dr Peter Arthur, Senior Lecturer, The University of Western Australia	Ongoing	£50,000
Fibrosis	Dr Lee Borthwich, University of Newcastle	Ongoing	£10,000
New ways of delivering Gene Therapy	EVOX Therapeutics	Ongoing	£200,000
Understanding heart disease in DMD	Dr John Bourke, Freeman Hospital	Ongoing	£67,000
Investigating soy products as a treatment for DMD	Prof Steve Winder, University of Sheffield	Ongoing	£30,500
Preclinical study of the combination of tamoxifen, L-citrulline and metformin	Dr Olivier Dorchies, University of Geneva	Ongoing	£200,000
Use of Elastase Inhibitors to Treat DMD	Dr Addolorata Pisconti, University of Liverpool	Ongoing	£36,365
Duchenne Clinical Research Nurse	Alder Hey Children's Hospital, Liverpool	Ongoing	£32,107
F2 Neuromuscular Clinical Research Doctor	Alder Hey Children's Hospital, Liverpool	Complete	£30,513
ST4 Neuromuscular Clinical Research Doctor	Alder Hey Children's Hospital, Liverpool	Complete	£127,121
Tamoxifen Clinical Trial	Dr Dirk Fischer, University Children's Hospital Basel	Ongoing	£194,997
Tamoxifen Project Manager	Dr Dirk Fischer, University Children's Hospital Basel	Ongoing	£97,000
TREAT-NMD DMD Co-Ordinator Role	University of Newcastle	Ongoing	£78,833
Physiotherapist	Alder Hey Children's Hospital, Liverpool	Complete	£45,960
Duchenne Clinical Trial Nurse	Royal Victoria Infirmary, Newcastle	Complete	£22,500
Co-Funded Lectureship for a Clinical Research Lectureship/ Senior Lectureship in Duchenne Muscular Dystrophy	Dr Guglieri, University of Newcastle	Ongoing	£35,714
Assessing the preclinical therapeutic impact of cannabidiol for DMD	Dr Keith Foster, The University of Reading	Complete	£6,213
The Duchenne Forum, Supporting 8 basic research projects	Muscular Dystrophy Campaign	Complete	£55,346
Gene therapy	Solid GT, Boston, USA	Complete	\$1,666,667
VBP-15, Phase 1 Clinical Trial	Reveragen BioPharma Inc, USA	Complete	\$400,000
DMD Heart Protection Study	Dr Spinty, Alder Hey	Complete	£14,000
Phase1/2 Clinical trial of HT-100	Akashi Therapeutics, USA	Complete	\$100,000
Developing biomarkers for Utrophin Modulators	Summit Corporation, Oxford, UK	Complete	£100,000

JOINING JACK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2025

Financial review

Results for the year are shown in the Statement of Financial Activities on page 16.

Investment policy and objectives

The charity's investment policy is to retain all available funds on deposit to give sufficient liquidity to meet ongoing day-to-day needs.

Reserves policy

The Trustees have determined that a minimum unrestricted reserve of approximately £10,000 is required to ensure the ongoing operations of the charity. The charity does not require a significant restricted reserve because it does not currently have material fixed costs. The charity recognises it may be appropriate to allow the reserve to fluctuate as a result of short-term cash inflows and outflows and to ensure the funding of projects to which it is contractually committed.

Plans for future periods

Our future plans:

In the coming year we plan to:

- Through DMD Care UK continue to implement the new Standards of Care
- Provide education to families on research and care
- Provide psychological support to families and patients living with Duchenne through the pathway we develop
- Improve adult services to ensure all adults living with Duchenne get access to the best standards of care
- Continue to develop the Duchenne Hub.
- Create research opportunities for Adults with Duchenne by developing new outcome measures.
- Work to overcome the immunological issues preventing delivery of gene therapy.
- Advance research into the methods of delivery of gene therapy for Duchenne patients.
- Ensure adults with Duchenne receive the best standards of care
- Develop new outcome measures for clinical trials.
- Help optimise clinical trial designs
- Fund the next development phase of the SMART Suit arm assist product

Structure, governance and management

The charity is a unincorporated charity.

The charity is governed by its Declaration of Trust dated 28 February 2012, as amended by Deed dated 16 July 2012.

The trustees who served during the year and up to the date of signature of the financial statements were:

K Radlinski

A Kent

J Whitworth

JOINING JACK

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 30 APRIL 2025

Structure, governance and management Recruitment and appointment of new trustees

The trustees who have served during the year are set out on page 10. The trustees are appointed by the committee.

Organisational structure

The trustees meet on a regular basis to discuss the work and development of the organisation. The Scientific Advisory Board reviews applications for funding received from the pharmaceuticals sector and reports its findings back to the Board of Trustees.

Induction and training of new trustees

New trustees are given guidance provided by the committee which covers such items as roles and responsibilities, legal obligations under charity law, organisational structures and decision making processes, business planning and understanding financial information. The induction process also involves new trustees meeting key employees and other trustees. Trustees are encouraged to attend appropriate training events which will facilitate their understanding of their role and meet their individual training needs.

Auditor

Sumer Auditco Limited is eligible for appointment as auditor of the charity by virtue of its eligibility for appointment as auditor of a company under section 1212 of the Companies Act 2006.

Statement of Trustees' responsibilities

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that year.

In preparing these financial statements, the trustees are required to:


- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping sufficient accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

JOINING JACK

TRUSTEES' REPORT (CONTINUED) *FOR THE YEAR ENDED 30 APRIL 2025*

The Trustees' report was approved by the Board of Trustees.

Signed by:

7AF537EF35714438...
K Radlinski
Trustee

27 February 2026

JOINING JACK

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF JOINING JACK

Opinion

We have audited the financial statements of Joining Jack (the 'charity') for the year ended 30 April 2025 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the charity's affairs as at 30 April 2025 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the financial statements* section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the Trustees' report; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

JOINING JACK

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF JOINING JACK

Responsibilities of trustees

As explained more fully in the statement of Trustees' responsibilities, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

We identified areas of laws and regulations that could reasonable be expected to have a material effect on the financial statements from our general commercial and sector experience, through discussion with the trustees and other management (as required by auditing standards), and from inspection of the charity's regulatory and legal correspondence and discussed with the trustees and other management the policies and procedures regarding compliance with laws and regulations. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit. The potential effect of these laws and regulations on the financial statements varies considerably.

Firstly, the charity is subject to laws and regulations that directly affect the financial statements including financial reporting legislation (including related parties legislation), pensions legislation and taxation legislation, and we assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.

Secondly, the charity is subject to other laws and regulations where the consequences of non-compliance could have a material effect on amounts or disclosures in the financial statements, for instance through the imposition of fines, litigation or the loss of the charity's license to operate. We identified the following areas as those most likely to have such an effect: GDPR compliance, health and safety and product liability, anti-bribery and corruption, employment law, tax, environmental legislation, recognising the nature of the charities activities.

Auditing standards limit the required audit procedures to identify non-compliance with these laws and regulations to enquiry of the trustees and other management and inspection of regulatory and legal correspondence, if any. These limited procedures did not identify actual or suspected non-compliance.

JOINING JACK

INDEPENDENT AUDITOR'S REPORT (CONTINUED) TO THE TRUSTEES OF JOINING JACK

Owing to the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

We design procedures in line with our responsibilities, outlined below to detect material misstatement due to fraud:

- Matters are discussed amongst the audit engagement team regarding how and where fraud might occur in the financial statements and any potential indicators of fraud
- Identifying and assessing the design and effectiveness of controls that management have in place to prevent and detect fraud
- Detecting and responding to the risks of fraud following discussions with management and enquiring as to whether management have knowledge of any actual, suspected or alleged fraud;

A further description of our responsibilities is available on the Financial Reporting Council's website at: <https://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Other matters


Your attention is drawn to the fact that the charity has prepared financial statements in accordance with "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

This has been done in order for the financial statements to provide a true and fair view in accordance with current Generally Accepted Accounting Practice.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Signed by:



5EF5734B62A94DF...

Catherine Rogers BSc FCA (Senior Statutory Auditor)

For and on behalf of Sumer Auditco Limited, Statutory Auditor

Chartered Accountants

1st Floor Waterside House

Waterside Drive

Wigan

Lancashire

WN3 5AZ

27 February 2026

JOINING JACK

STATEMENT OF FINANCIAL ACTIVITIES INCLUDING INCOME AND EXPENDITURE ACCOUNT

FOR THE YEAR ENDED 30 APRIL 2025

	Notes	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Income from:			
Donations and legacies	3	397,424	238,372
Charitable activities	4	159,283	250,165
Investments	5	332,945	15,732
Total income		889,652	504,269
Expenditure on:			
Raising funds	6	166,515	208,584
Charitable activities	7	504,869	530,581
Other expenditure	13	1,504	924
Total expenditure		672,888	740,089
Net gains/(losses) on investments	14	(29,628)	11,191
Net income/(expenditure) and movement in funds		187,136	(224,629)
Reconciliation of funds:			
Fund balances at 1 May 2024		1,653,229	1,877,858
Fund balances at 30 April 2025		1,840,365	1,653,229

JOINING JACK

BALANCE SHEET
AS AT 30 APRIL 2025

	Notes	2025		2024	
		£	£	£	£
Fixed assets					
Tangible assets	15		105		131
Investments	16		23,768		53,396
			23,873		53,527
Current assets					
Stocks	17	222		322	
Debtors	18	-		85	
Cash at bank and in hand		1,826,384		1,607,845	
		1,826,606		1,608,252	
Creditors: amounts falling due within one year	19	(10,114)		(8,550)	
Net current assets			1,816,492		1,599,702
Total assets less current liabilities			1,840,365		1,653,229
The funds of the charity					
Unrestricted funds	20		1,840,365		1,653,229
			1,840,365		1,653,229

The financial statements were approved by the trustees on 27 February 2026

Signed by:

85D453C5D7B84B4...
J Whitworth
Trustee

JOINING JACK

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 30 APRIL 2025

	Notes	2025 £	£	2024 £	£
Cash flows from operating activities					
Cash absorbed by operations	22		(114,406)		(252,575)
Investing activities					
Investment income received		332,945		15,732	
Net cash generated from investing activities			332,945		15,732
Net cash generated from financing activities			-		-
Net increase/(decrease) in cash and cash equivalents			218,539		(236,843)
Cash and cash equivalents at beginning of year			1,607,845		1,844,688
Cash and cash equivalents at end of year			1,826,384		1,607,845

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2025

1 Accounting policies

Charity information

Joining jack is a unincorporated charitable company, and is registered in England and Wales. The company's registered office is: ADM Print, 16 Appleton Street, Wigan, Lancashire, WN3 4BZ.

1.1 Accounting convention

The financial statements have been prepared in accordance with the charity's governing document, the Charities Act 2011, FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Charities SORP "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)". The charity is a Public Benefit Entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives.

1.4 Income

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Dividends received

Dividend income receivable from investments is recognised in the period they are voted.

1.5 Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure

1.6 Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 APRIL 2025

1 Accounting policies (Continued)

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings	20% p.a. reducing balance basis
-----------------------	---------------------------------

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is recognised in the statement of financial activities.

1.7 Fixed asset investments

Social investments comprise programme related investments which are measured at cost less impairment.

1.8 Impairment of fixed assets

At each reporting end date, the charity reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any).

1.9 Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and moving items.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.10 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.11 Financial instruments

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 APRIL 2025

1 Accounting policies

(Continued)

Basic financial liabilities

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Derecognition of financial liabilities

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

1.12 Taxation

The charity is exempt from tax on its charitable activities.

1.13 Employee benefits

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.14 Retirement benefits

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

Carrying value of social investments

Fixed asset investments relates to social investments included in the financial statements at fair value of £23,768 (2024: £53,396). The directors have assessed the fair value at the period end based on the financial position of Duchenne Research (UK) Investment Ltd [DRIL]. The purpose of DRIL is to invest in SOLID Biosciences. In the year ended 30th April 2025 the share price of SOLID Biosciences has now decreased resulting in a downward revaluation of the investment of £29,628 (2024: £11,191 upward valuation).

Refer to Note 16 for the carrying value of social investments impacted by this key accounting estimate.

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 APRIL 2025

3 Income from donations and legacies

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Donations and gifts	397,424	238,372

4 Income from charitable activities

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Fundraising Events	158,894	248,362
Merchandise Sales	389	1,803
	159,283	250,165

5 Income from investments

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Income from unlisted investments	311,735	-
Interest receivable	21,210	15,732
	332,945	15,732

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 APRIL 2025

6 Expenditure on raising funds

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Fundraising and publicity		
Staging fundraising events	77,235	105,981
Other fundraising costs	6,874	27,921
Staff costs	65,657	61,418
	<u>149,766</u>	<u>195,320</u>
Trading costs		
Operating charity shops	1,448	3,313
Other trading activities	1,200	2,400
Depreciation and impairment	26	33
Support costs	14,075	7,518
	<u>16,749</u>	<u>13,264</u>
Total costs	<u>166,515</u>	<u>208,584</u>

7 Expenditure on charitable activities

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Direct costs		
Grant funding of activities (see note 8)	504,869	530,581
	<u>504,869</u>	<u>530,581</u>
Analysis by fund		
Unrestricted funds	504,869	530,581
	<u>504,869</u>	<u>530,581</u>

8 Grants payable

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Grants to institutions:		
Duchenne UK Grant Call	504,869	530,581
	<u>504,869</u>	<u>530,581</u>

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 APRIL 2025

9 Support costs allocated to activities

	2025 £	2024 £
Governance costs	14,075	7,518
Analysed between:		
Other resources expended	14,075	7,518

10 Auditor's remuneration

Fees payable to the charity's auditor and associates:	2025 £	2024 £
For audit services		
Audit of the financial statements of the charity	9,000	5,730

11 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits from the charity during the year.

Trustees' expenses

There were no trustees' expenses paid for the year ended 30 April 2025 nor for the year ended 30 April 2024.

12 Employees

The average monthly number of employees during the year was:

	2025 Number	2024 Number
Costs of generating voluntary income	2	2
Research and campaigning	1	1
Total	3	3

Employment costs

	2025 £	2024 £
Wages and salaries	65,657	61,418

There were no employees whose annual remuneration was more than £60,000.

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 APRIL 2025

13 Other expenditure

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Pensions	1,504	924

14 Gains and losses on investments

	Unrestricted funds 2025 £	Unrestricted funds 2024 £
Gains/(losses) arising on:		
Revaluation of investments	(29,628)	11,191

15 Tangible fixed assets

	Fixtures and fittings £
Cost	
At 1 May 2024	1,461
At 30 April 2025	1,461
Depreciation and impairment	
At 1 May 2024	1,330
Depreciation charged in the year	26
At 30 April 2025	1,356
Carrying amount	
At 30 April 2025	105
At 30 April 2024	131

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 APRIL 2025

16 Fixed asset investments

	Social Investments £
Cost or valuation	
At 1 May 2024	53,396
Valuation changes	(29,628)
At 30 April 2025	23,768
Carrying amount	
At 30 April 2025	23,768
At 30 April 2024	53,396

Joining Jack is a shareholder in Duchenne Research (UK) Investment Ltd [DRIL], a company incorporated in the UK as a company limited by shares on 9 December 2014.

Alex Johnson, one of the founders of Joining Jack, is a director of DRIL.

The purpose of DRIL is to invest in SOLID Biosciences. SOLID Biosciences undertakes gene therapy-based research into Duchenne Muscular Dystrophy and drug development and treatments in connection therewith. SOLID Biosciences is listed on Nasdaq.

In October 2022, SOLID Biosciences implemented a 1-for-15 reverse split of its common stock, resulting in the number of shares held by DRIL reducing from 520,477 to 34,698. As a result, the share price of SOLID Biosciences increased in year ended 30th April 2024. However, in the year ended 30th April 2025, the share price of SOLID Biosciences has now decreased, resulting in a downward revaluation of the investment of £29,628 (2024: £11,191 upwards revaluation).

Further commentary regarding the charity's investment in DRIL is included in the financial review section of the Trustee's Report.

17 Stocks

	2025 £	2024 £
Finished goods and goods for resale	222	322

18 Debtors

	2025 £	2024 £
Amounts falling due within one year:		
Other debtors	-	85

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 30 APRIL 2025

19 Creditors: amounts falling due within one year

	2025 £	2024 £
Other taxation and social security	837	-
Other creditors	277	(650)
Accruals and deferred income	9,000	9,200
	<u>10,114</u>	<u>8,550</u>

20 Unrestricted funds

The unrestricted funds of the charity comprise the unexpended balances of donations and grants which are not subject to specific conditions by donors and grantors as to how they may be used. These include designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

	At 1 May 2024 £	Incoming resources £	Resources expended £	Gains and losses £	At 30 April 2025 £
General funds	<u>1,653,229</u>	<u>889,652</u>	<u>(672,888)</u>	<u>(29,628)</u>	<u>1,840,365</u>
Previous year:	At 1 May 2023	Incoming resources	Resources expended	Gains and losses	At 30 April 2024
	£	£	£	£	£
General funds	<u>1,877,858</u>	<u>504,269</u>	<u>(740,089)</u>	<u>11,191</u>	<u>1,653,229</u>

21 Related party transactions

There were no disclosable related party transactions during the year (2024 - none).

22 Cash absorbed by operations

	2025 £	2024 £
Surplus/(deficit) for the year	187,136	(224,629)
Adjustments for:		
Investment income recognised in statement of financial activities	(332,945)	(15,732)
Fair value gains and losses on investments	29,628	(11,191)
Depreciation and impairment of tangible fixed assets	26	33
Movements in working capital:		
Decrease in stocks	100	-
Decrease in debtors	85	400
Increase/(decrease) in creditors	1,564	(1,456)
Cash absorbed by operations	<u>(114,406)</u>	<u>(252,575)</u>

JOINING JACK

England & Wales - Charity number 1148156

Accounts

**Report of the Trustees and
Financial Statements
for the Year Ended 30 April 2024
for
JOINING JACK**

NRB
1st Floor Waterside House
Waterside Drive
Wigan
Lancashire
WN3 5AZ

JOINING JACK

Contents of the Financial Statements FOR THE YEAR ENDED 30 APRIL 2024

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 10
Report of the Independent Auditors	11 to 13
Statement of Financial Activities	14
Balance Sheet	15
Notes to the Financial Statements	16 to 22
Detailed Statement of Financial Activities	23

JOINING JACK

Reference and Administrative Details FOR THE YEAR ENDED 30 APRIL 2024

Trustees	Mr J Whitworth Ms A Kent Mr K Radlinski
Principal address	c/o ADM Leisurewear Ltd Unit 1 Appleton Street Wigan Lancashire WN3 4BZ
Registered charity number	1148156
Auditors	NRB 1st Floor Waterside House Waterside Drive Wigan Lancashire WN3 5AZ

JOINING JACK

Report of the Trustees FOR THE YEAR ENDED 30 APRIL 2024

The trustees present their report with the financial statements of the charity for the year ended 30 April 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Objectives and activities

Objectives and activities for the public benefit

Charitable objectives are; to relieve the needs of sufferers of Duchenne Muscular Dystrophy (DMD), speed up treatments for all children and adults living with DMD by funding research into methods of treatment and a cure for the condition

Objectives and activities

Significant activities

On 22 April 2016 Joining Jack joined forces with Duchenne UK, another parent-led charity formerly called The Duchenne Children's Trust, set up by Emily and Nick Crossley.

Joining Jack remains a separate charity and holds stand-alone fundraising events but now shares a research strategy, scientific advisory board and Director of Research with Duchenne UK.

Research

A post year end Research Project Report, dated December 2024, from Alessandra Gaeta, Director of Research for Duchenne UK & Joining Jack, (Joining Jack & DUK Research Portfolio End of Year report 2024) provides a progress update on all the projects funded by Joining Jack in the Duchenne UK portfolio.

This is an overview of new funding opportunities in the pipeline. The report covers active projects and projects that have completed in 2024. Historical projects which have closed in 2023 and before are not included. For each funded project, a status, update on progress and update on funding is included.

Our research strategy has now expanded to include six key elements to it, all of which are integral to accelerating and advancing research. Funding the research is the first crucial step but on its own it isn't enough. We need to look at the overall landscape of research and drug development, and our strategy has been developed to reflect this.

1) Fund and accelerate research for early stage clinical trials

Our approach is 100% focused on advancing research and getting treatments into clinic and to patients as quickly as possible. Working alongside co-founder of Duchenne UK Emily Crossley, our co-founder, Alex Johnson, actively seeks out projects and potential therapies which could benefit the current generation of patients. We run an international grant call. We invest globally in basic science, translational research and clinical trials.

2) Facilitate and accelerate research

We are committed to accelerating the pace of research, ensuring that we remove potential obstacles and roadblocks that lie in the path of drug development. It is vital that the research we fund has the potential to translate into clinical trials, and so we fund the doctors, nurses and physiotherapists necessary to conduct trials in the UK. We created and expanded the DMD Hub which has the ambition that every child born with Duchenne in the UK has the opportunity to take part in research. We also support and encourage national and international collaboration to allow researchers and clinicians to collaborate and progress research. We are proud to support the Treat-NMD network and their bi-annual TACT meetings to review potential clinical trials for Duchenne muscular dystrophy.

3) Implementation of the Standards of Care (SoC) in the UK

The updated SoC were published in The Lancet of Neurology in 2018. They are ambitious and significantly advance on the 2010 version. While this is welcomed by families and clinicians, it presents challenges at a national level where the health care systems need to increase or change provision, and in many cases increase resources in order to deliver the fully updated SoC. We have launched a new project DMD Care UK to tackle this issue. The project will ensure everyone in the UK living with Duchenne has access to the best care.

JOINING JACK

Report of the Trustees FOR THE YEAR ENDED 30 APRIL 2024

4) Work alongside industry

We work with industry, advising on clinical trial designs. We have advised on the protocols of a number of different trials. We work with Project Hercules and their industry partners to help collect the data they need to aid reimbursement decisions of drugs.

5) Continued engagement with regulators and policy makers

We are engaging with policy makers and regulators on many issues, from campaigning for Early Access to Medicines to engaging with the Health Technology Appraisal system.

6) Collaborate with families and charities globally

We work with families to empower them to get the best access to care and treatments for their children. We work with Duchenne UK to stage free Patient Information days across the UK, and in February 2024 we staged our first international conference in London. Alex Johnson also sits on the board of the World Duchenne Organisation to ensure we collaborate with charities internationally.

Objectives and activities

Our Scientific Advisory Board (SAB) is a fundamental part of our project review process - and ensures our supporters' donations are being invested in the right projects to advance the DMD field. For several years now, we have been proud to work with the following experts:

Prof Giovanni Baranello
Dr John Bourke, Newcastle University, UK
Prof Dame Kay Davies, University of Oxford, UK
Prof Annemieke Aartsma-Rus, Leiden University Medical Centre, Netherlands
Prof Jordi Diaz Manera
Dr Tina Duong
Dr Dada Pisconti, Stonybrook University, USA
Dr Isabelle Richard
Dr Valeria Ricotti
Dr Carina Schey
Prof Francesco Saverio Tedesco
Dr Graeme Wilkinson

These are all researchers at the top of their field and are generous enough to share their expertise and knowledge, regardless of the huge demands on their time.

Volunteers

The charity has an incredible ever-growing army of volunteers who enable the staging of our flagship fundraising multi-participant events. An existing database of more than 150 names alongside local running and cycling clubs and Army Cadets, are called upon to help with pre-event preparation (goodie bag packing and race/ride packs) and on the day to hand out medals, water, refreshments marshal routes and support runners/riders at the start and finish.

Our volunteer database continues to grow to help us create and stage the four mass participation events.

JOINING JACK

Report of the Trustees FOR THE YEAR ENDED 30 APRIL 2024

Achievement and performance

Fundraising activities

Run Wigan Festival

2017 saw us launch two new flagship fundraising events the first of which was the Run Wigan Festival in March featuring a Half Marathon, a 5k and Family Mile run. The event celebrated its third year in 2019 when a fourth distance was introduced to the event in the shape of a 10 Miler. The race was a sell-out.

The 4th Run Wigan Festival in 2020, was cancelled with less than a week to go, due to COVID and eventually staged virtually and a date was never officially set for the 2021 event due to the ongoing restrictions and a third national Lockdown, meaning we were unable to stage the event for two years. The Run Wigan Festival returned in 2022 and included 329 deferred entries from 2020, while all runners who had taken part in the Virtual Run Wigan Festival of 2020 were offered a 25% discount for their support throughout the ongoing cancellations and to maintain engagement with the charity's established event network. This did have an effect on fundraising and did mean that the event could have potentially run at a loss but the Trustees, along with the co-founders, and Race Director were in agreement that it was important to stage the event and honour the deferrals and discount codes to maintain the charity and the event's reputation. This would be the final event to be affected financially as a knock-on effect of COVID and Lockdowns and turned around £10,000 profit.

The Run Wigan Festival moved to a new home in 2023 following in the footsteps of the Wigan 10k and relocating to Mesnes Park. This involved a few tweaks to the routes and a bigger section of the flagship HM race taking place along the canal requiring increased volunteer and steward numbers. The relocation and route tweak proved a success and provided promising signs for the event to build on as we continue to navigate out of the devastation caused to mass participation events as a result of COVID's legacy. £13,000 was raised, a slight increase on 2022.

The 2024 Run Wigan Festival remained at Mesnes Park and, building on the green shoots from the 2023 event, numbers continued to rise. The event proved to be our biggest March flagship fundraiser since 2018!

NUMBERS: 1,202 Half Marathon 875 5k 318 (& 160 on day) Family Mile TOTAL: 2,555

The event raised £30,000 - more than doubling the 2023 total.

The date for the 2025 Run Wigan Festival has been set for Sunday, March 16, and we are delighted to report that numbers are ahead of 2024 at this point in the registration process. We are confident of beating last year's totals in both numbers and fundraising.

Wigan Bike Ride

After three years of taking part as a team in organised Bike Rides, the charity made the decision to stage its first ever organised bike ride on July 22nd 2017 under the Title Sponsorship of Develop UK and featuring a 50 Mile main ride on open roads and a 5 Mile family ride on closed roads.

The 4th Bike Ride in 2020 was cancelled due to the ongoing pandemic and took place as a virtual event with 278 riders participating with support from all over the north-west and UK and from across the world.

The charity's first mass participation flagship fundraising event since the pandemic was the 5th Bike Ride in 2021 at a change of venue due to availability just before COVID guidelines were fully relaxed so social distancing was maintained outdoors. New Hardcore and Highway routes were introduced for the 50 mile ride.

The 2022 Bike Ride returned to its original home of Mesnes Park and the welcome return of the 5 Mile Family Ride - the first time this had been staged since 2019. In 2023, the 7th Wigan Bike Ride took place in soaring temperatures.

Under the continued Title Sponsorship of Develop UK, the 2023 event £18,500 raised, numbers slightly down on the previous year but a small increase in fundraising. A total of £168,000 raised from the Bike Ride to date

The date for the 2024 8th Wigan Bike Ride was provisionally set for Sunday, June 23, although not announced and registration was not launched. Due to a change in circumstances affecting the events team, a decision was taken early in the year not to stage the Bike Ride and concentrate on the running events.

JOINING JACK

Report of the Trustees FOR THE YEAR ENDED 30 APRIL 2024

Wigan 10k

Due to the ongoing works in the town centre, the decision was taken to relocate our inaugural flagship fundraising event the Wigan 10k (first staged in 2013), to Mesnes Park in 2022 when we invited vendors to provide food and drink options for runners. There was also a return to live entertainment following the race - the first time since COVID.

Final numbers were disappointing which we believe, having spoken to our Event Partners and other Race organisers, is an ongoing consequence of COVID, and the cost of living crisis. However, the new Start/Finish, along with food and drink vendors at Event HQ proved to be an overwhelming success.

Since the disappointing numbers of 2022, the event now seems to have turned a corner and numbers have been on the up. 2023 saw us sell out at 1,900 runners in the 10k race raising £35,000 and last year's event made further huge strides, selling out at 2,900 10k runners - our highest total since 2017.

NUMBERS: 2,900 10k 265 (& 150 on day) Family Mile TOTAL: 3,315

The 2024 event raised a fantastic £50,000 - another significant increase on the previous year. It is a continually encouraging picture for our events-based fundraising and we hope to continue that trend with further increases in 2024.

The date for the 2025 Wigan 10k has been set for Sunday, September 7th. Given the promising numbers that took part in 2024, we have targeted 3,000 runners taking us closer to totals achieved before the pandemic. The encouraging news is that we are already ahead of where we were at this point last year.

Fundraising 2024 Summary

The charity relies heavily on our own flagship events and supporters taking part in mass participation events. Many if not all of these were cancelled in 2020 and in the first half of 2021 due to COVID-19 Coronavirus. This had a significant effect on the charity's income both in 2020 and 2021 and has also affected overall fundraising income in 2022 with a continued knock-on effect of deferrals and discounted entries in the Run Wigan Festival 2022, our first event of the year.

With the cost of living crisis also having an effect on numbers taking part, the overall fundraising total for 2022 was around 25% of what the charity has previously raised. However, 2023 looked to be an indication of a significant turning point for events and fundraising and 2024 certainly continued that trend. The return to higher numbers taking part saw our biggest events since 2018 in March and 2017 in September. We hope to continue that in 2025 to get back to somewhere close to the record numbers.

In 2024, the combined total fundraising from the two flagship running events totalled £80,000.

Other fundraising initiatives 2023

CAMPAIGNS, COMMUNITY WORK & RECOGNITION

The charity was supported by a number of events ranging from a Valentine's Ball, organised by sisters Kate Whitworth and Georgina McAuley, in February. Team JJ and volunteers were fundraising on the night, with the event raising an incredible £88,000, to a dinner by the team from Aston Martin, which Alex attended, which donated 50% of funds raised for a fantastic donation of £65,000. We were also chosen as Charity of the Year by a number of sporting and activity clubs, and individual fundraisers.

Jack and the charity team were invited to attend the Wigan All Stars ceremony at the Town Hall, having been chosen to receive a Star in the Walk of Fame back in 2022 to mark 10k year anniversary, underlining the continued community and civic support.

Alex, Jack's mum and co-founder of the charity, received her OBE from the Princess Royal, Princess Anne, attending Windsor Castle with Andy, Jack and James and great coverage from ITV.

Alongside our partner Charity Duchenne UK, we were part of the New Horizons team, the first two-day conference, in March. The conference brought together people from all across our community. At it we met the parents of children who have recently been diagnosed with DMD, as well as people we have forged a friendship for over a decade as a result of sharing our rare reality.

Jack completed his GCSE examinations, attended prom and successfully applied to attend college as part of his post-16 education. In the summer he completed a work experience placement with Wigan Warriors. He also increased his extra-curricular sporting achievement promoting the Powerchair Hockey league and took part in the Dystrophy Diaries podcast.

JOINING JACK

Report of the Trustees FOR THE YEAR ENDED 30 APRIL 2024

Jack has also been at the forefront of the charity's campaign work - 2% Campaign to improve seating access for wheelchair users at sporting and live events, meeting with Culture Secretary Lisa Nandy, and he was also invited to London to meet with the CEO of the MHRA as part of early access to medicines campaign. This is all part of Jack's drive to take a more leading role in the charity's campaign work.

As well as campaign and awareness work, the Joining Jack team have been promoting the charity's flagship events along with individual supporters and team contributions and donations. We also promote our own merchandise through Ebay for Charity Shop which provides a steady source of income. The charity has also had continued support from sponsors, event partners and supporters throughout the year including two new Associate Sponsors for the Wigan 10k in 2024, which is positive support going forward.

IMPACT

Our battle against Duchenne muscular dystrophy is heading into its 13th year. We have included an update on how the work of Joining Jack alongside our partners and the national parent charity Duchenne UK, is making significant progress in many different areas. This includes:

- The approval of Vamorolone by the FDA and EMA. This is the first drug for all people with DMD, which Duchenne UK played a key role in developing.
- While our Project HERCULES is helping support the health technology assessment of Vamorolone, which is currently being appraised by NICE.
- We launched a new project to drive better care for nutrition and weight management in DMD.
- The third version of our SMART Suit prototype has been developed and is being tested.
- Our psychosocial programme has developed a referral pathway for children with DMD and patients are now being referred to it.
- Our DMD Care UK programme published a new bone health guide for people with DMD and their families.
- Our DMDhome digital platform has entered the validation phase. DMDhome uses video capture and computer vision analysis to measure limb function in DMD. The study will aim to validate this new approach for use in clinical trials and potentially in the approval of new medicines for DMD.
- Our Central Recruitment Database has moved on from the pilot stage. Every commercial DMD trial opened in the UK since its establishment has recruited patients using it.
- We are undertaking extensive research with young people with DMD to completely rethink how wheelchairs can help them live their lives.

Helping the DMD heart

There has been important progress in DMD research over the last decade, and yet there is still a lack of understanding of the DMD heart and how to treat it. This is very serious for DMD treatment and care. To address this gap, we launched a grant call in February 2024. This is an investment up to £1.5 million to fund research into understanding and treating people with DMD, including their hearts. Introducing Elevox

We are partnering with the charity Spinal Muscular Atrophy UK and the University of Liverpool's Inclusionaries Lab on ensuring we have the expertise we need, and helping to accelerate the development process and get the product to market sooner.

And we are doing so with a user-led product design strategy. Since taking on the project in 2022, we've conducted lots of in-depth research and built four working prototypes that we've tested with people who have either DMD or Spinal Muscular Atrophy (SMA).

Now called Elevox, we will continue to refine and test the prototype with user-led input, and we're on schedule to have the final device ready for people with DMD and SMA by the end of 2025.

We are excited and hopeful about launching a suit that will have a meaningful impact on their lives.

Leading the way to new DMD treatments

Developing new treatments for DMD is only half the battle, ensuring access to them is the other half.

We were delighted when a treatment that we have supported the development of, in a ground-breaking example of venture philanthropy, was approved for use in NHS England.

JOINING JACK

Report of the Trustees FOR THE YEAR ENDED 30 APRIL 2024

The National Institute for Health and Care Excellence (NICE) approved vamorolone for use on the NHS to treat DMD in December 2024. Vamorolone, also known by the brand name Agamree, will be available to treat people with DMD aged four years and older.

Vamorolone was created as an alternative to existing corticosteroids, which are routinely used in the treatment of DMD. Steroid treatment has several negative side-effects, and some DMD patients do not tolerate it well or at all. Vamorolone now gives their neuromuscular consultant a new treatment option for them.

The full Impact Report 2024 will be available to view on our website and published across social channels early in 2025.

Funding and research decisions

We have listed in the table below a list of the grants we have awarded to date. We have colour-coded the grants to show how we are supporting the whole therapeutic development pipeline. Joining Jack is committed to ensuring that as much as possible of our funds goes to developing research into a treatment or a cure for Duchenne Muscular Dystrophy.

We are particularly focused on transitional research, research that takes potential therapeutics out of laboratories and into clinical trials. Working closely with our partner charity Duchenne UK, our trusted team of scientific advisors, patient advisory board and trustees, we have made major decisions on how to spend the funds raised. The grants that we have been awarded have led to breakthroughs that are changing the therapeutic landscape for the Duchenne community.

DMD Care UK = Red
Basic Research = Yellow
Preclinical Research = Green
Clinical Trial Support = Blue
Clinical Trials = Orange

JOINING JACK

Report of the Trustees FOR THE YEAR ENDED 30 APRIL 2024

Project Name	Research/Institution or Company	Project Status	Total Grant Award
Smart Suit Project	Spinal Muscular Atrophy UK (SMA UK) & University of Liverpool	Ongoing	£150,000
DMD Care Phase 2	Newcastle University	Ongoing	£150,000
DMD Hub research Fellow/ Clinical Trial Support	Dr Anne-Marie Childs, Leeds Children's Hospital	Ongoing	£35,000
Home-based video assessment of DMD	Aparito	Ongoing	£173,336
DMD Care Neuropsychiatrist	University of Glasgow	Complete	£75,000
Antifibrotic/antiadipogenic drug Fibrogenesis	Newcastle University	Complete	£32,688
Hydrotherapy Clinical Trial	Dr De Goede, Royal Preston Hospital	Started	£118,000
Immunology Grant Call Award	Professor Kannaboina Nagaraju at Binghamton, the State University of New York	Started	£1,000
Biomarker Trial	Duke University	Started	£20,000
Dream Chair development	Whizz Kidz	Ongoing	£50,000
DMD Care UK	Newcastle University	Ongoing	£140,000
Immunology Grant	University of Florida	Ongoing	£185,000
Splint Trial	Newcastle University	Started	£10,000
Stem Cells	University of Minnesota	Started	£140,000
Vitamin B3	Leiden University	Started	£10,000
Tackling fibrosis and muscle regeneration	Agada Biosciences	Started	£25,000
Repurposing Drugs	Dr Olivier Dorchies, University of Geneva	Started	£25,000
Testosterone extension	Prof Volker Straub, University of Newcastle	Started	£10,000
Adult NMCCC	Dr Chiara Marini-Bettolo, University of Newcastle	Ongoing	£10,000
Open label extension study for Tamoxifen	Dr Dirk Fischer, University Children's Hospital Basel	Pending	£230,000.00
Taurine	Dr Peter Arthur, Senior Lecturer, The University of Western Australia	Ongoing	£50,000
Fibrosis	Dr Lee Borthwick, University of Newcastle	Ongoing	£10,000
New ways of delivering Gene Therapy	EVOX Therapeutics	Ongoing	£200,000
Understanding heart disease in DMD	Dr John Bourke, Freeman Hospital	Ongoing	£67,000.00
Investigating soy products as a treatment for DMD	Prof Steve Winder, University of Sheffield	Ongoing	£30,500
Preclinical study of the combination of tamoxifen, L-citrulline and metformin	Dr Olivier Dorchies, University of Geneva	Ongoing	£200,000
Use of Elastase Inhibitors to Treat DMD	Dr Addolorata Pisconti, University of Liverpool	Ongoing	£36,365.00
Duchenne Clinical Research Nurse	Alder Hey Children's Hospital, Liverpool	Ongoing	£32,106.50
F2 Neuromuscular Clinical Research Doctor	Alder Hey Children's Hospital, Liverpool	Complete	£30,513
ST4 Neuromuscular Clinical Research Doctor	Alder Hey Children's Hospital, Liverpool	Complete	£127,121.00
Tamoxifen Clinical Trial	Dr Dirk Fischer, University Children's Hospital Basel	Ongoing	£194,996.99
Tamoxifen Project Manager	Dr Dirk Fischer, University Children's Hospital Basel	Ongoing	£97,000
TREAT-NMD DMD Co-Ordinator Role	University of Newcastle	Ongoing	£78,832.66
Physiotherapist	Alder Hey Children's Hospital, Liverpool	Complete	£45,960.00

JOINING JACK

Report of the Trustees FOR THE YEAR ENDED 30 APRIL 2024

Project Name	Research/Institution or Company	Project Status	Total Grant Award
Duchenne Clinical Trial Nurse	Royal Victoria Infirmary, Newcastle	Complete	£22,500
Co-Funded Lectureship for a Clinical Research Lectureship/ Senior Lectureship in Duchenne Muscular Dystrophy	Dr Guglielmi, University of Newcastle	Ongoing	£35,714.30
Assessing the preclinical therapeutic impact of cannabidiol for DMD	Dr Keith Foster, The University of Reading	Complete	£6213.09
The Duchenne Forum, Supporting 8 basic research projects	Muscular Dystrophy Campaign	Complete	£55,346.00
Gene therapy	Solid GT, Boston, USA	Complete	\$1,666,666.66
VBP-15, Phase 1 Clinical Trial	Reveragen BioPharma Inc, USA	Complete	\$400,000.00
DMD Heart Protection Study	Dr Spinty, Alder Hey	Complete	£14,000
Phase1/2 Clinical trial of HT-100	Akashi Therapeutics, USA	Complete	\$100,000
Developing biomarkers for Utrophin Modulators	Summit Corporation, Oxford, UK	Complete	£100,000

Financial review

Financial position

Results for the year are shown in the Statement of Financial Activities on page 14.

SEE WORD VERSION

Investment policy and objectives

The charity's investment policy is to retain all available funds on deposit to give sufficient liquidity to meet ongoing day-to-day needs.

Reserves policy

The Trustees have determined that a minimum unrestricted reserve of approximately £10,000 is required to ensure the ongoing operations of the charity. The charity does not require a significant restricted reserve because it does not currently have material fixed costs. The charity recognises it may be appropriate to allow the reserve to fluctuate as a result of short-term cash inflows and outflows and to ensure the funding of projects to which it is contractually committed.

Future plans

Our future plans

In the coming year we plan to:

- Through DMD Care UK continue to implement the new Standards of Care and also launch a Transition grant call.
- Provide education to families on research and care.
- Provide psychological support to families and patients living with Duchenne through the pathway we develop.
- Continue to develop the Duchenne Hub.
- Create research opportunities for Adults with Duchenne by developing new outcome measures.
- Work to overcome the immunological issues preventing delivery of gene therapy.
- Advance research into the methods of delivery of gene therapy for Duchenne patients.
- Bring the Dream Chair to market.
- Develop new outcome measures for clinical trials.
- Help optimise clinical trial designs
- Fund the next development phase of the SMART Suit arm assist product

Structure, governance and management

Constitution

The charity is governed by its Declaration of Trust dated 28 February 2012, as amended by Deed dated 16 July 2012.

JOINING JACK

Report of the Trustees FOR THE YEAR ENDED 30 APRIL 2024

Structure, governance and management

Recruitment and appointment of new trustees

The trustees who have served during the year are set out on page 1. The trustees are appointed by the committee.

Organisational structure

The trustees meet on a regular basis to discuss the work and development of the organisation. The Scientific Advisory Board reviews applications for funding received from the pharmaceuticals sector and reports its findings back to the Board of Trustees.

Induction and training of new trustees

New trustees are given guidance provided by the committee which covers such items as roles and responsibilities, legal obligations under charity law, organisational structures and decision making processes, business planning and understanding financial information. The induction process also involves new trustees meeting key employees and other trustees. Trustees are encouraged to attend appropriate training events which will facilitate their understanding of their role and meet their individual training needs.

Statement of trustees' responsibilities

Responsibilities of the Board of Trustees:

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the charity and the surplus or deficit of the charity for that period. In preparing these statements, the trustees are required to:


- Select suitable accounting policies and apply them consistently;
- Make judgements and estimates that are reasonable and prudent;
- Follow applicable accounting standards, subject to any material departures disclosed and explained in the financial statements;
- Prepare financial statements on an ongoing basis unless inappropriate to assume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Trustees who served during the period:

- Jonathan Whitworth (appointed May 16th 2014)
- Andrea Kent (appointed May 16th 2014)
- Kristian Radlinski (appointed May 16th 2014)

Approved by order of the board of trustees on 24/02/2025 and signed on its behalf by:



Ms A Kent - Trustee

Report of the Independent Auditors to the Trustees of Joining Jack

Opinion

We have audited the financial statements of Joining Jack (the 'charity') for the year ended 30 April 2024 which comprise the Statement of Financial Activities, the Balance Sheet and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 30 April 2024 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Trustees of Joining Jack

Our responsibilities for the audit of the financial statements

We have been appointed as auditors under Section 145 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

We identified areas of laws and regulations that could reasonable be expected to have a material effect on the financial statements from our general commercial and sector experience, through discussion with the trustees and other management (as required by auditing standards), and from inspection of the charity's regulatory and legal correspondence and discussed with the trustees and other management the policies and procedures regarding compliance with laws and regulations. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit.

The potential effect of these laws and regulations on the financial statements varies considerably.

Firstly, the charity is subject to laws and regulations that directly affect the financial statements including financial reporting legislation (including related parties legislation), pensions legislation and taxation legislation, and we assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.

Secondly, the charity is subject to other laws and regulations where the consequences of non-compliance could have a material effect on amounts or disclosures in the financial statements, for instance through the imposition of fines or litigation. We identified the following areas as those most likely to have such an effect: GDPR compliance, health and safety and product liability, anti-bribery and corruption, employment law, tax, environmental legislation, recognising the nature of the charities activities. Auditing standards limit the required audit procedures to identify non-compliance with these laws and regulations to enquiry of the trustees and other management and inspection of regulatory and legal correspondence, if any. These limited procedures did not identify actual or suspected non-compliance.

Owing to the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

**Report of the Independent Auditors to the Trustees of
Joining Jack**

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

A handwritten signature in black ink, consisting of the letters 'NRB' in a stylized, cursive font.

NRB
1st Floor Waterside House
Waterside Drive
Wigan
Lancashire
WN3 5AZ

Date: 25/02/2025

JOINING JACK

Statement of Financial Activities FOR THE YEAR ENDED 30 APRIL 2024

		30.4.24 Unrestricted fund £	30.4.23 Total funds £
INCOME AND ENDOWMENTS FROM	Notes		
Donations and legacies	2	238,372	92,281
Other trading activities	3	250,165	81,375
Investment income	4	<u>15,732</u>	<u>227</u>
Total		<u>504,269</u>	<u>173,883</u>
 EXPENDITURE ON			
Raising funds	5	201,066	137,338
Charitable activities	6		
Funding research		530,581	486,124
Other		<u>(2,749)</u>	<u>41,694</u>
Total		<u>728,898</u>	<u>665,156</u>
 NET INCOME/(EXPENDITURE)		(224,629)	(491,273)
 RECONCILIATION OF FUNDS			
Total funds brought forward		<u>1,877,858</u>	<u>2,369,131</u>
 TOTAL FUNDS CARRIED FORWARD		<u><u>1,653,229</u></u>	<u><u>1,877,858</u></u>

The notes form part of these financial statements

JOINING JACK

Balance Sheet 30 APRIL 2024

	Notes	30.4.24 Unrestricted fund £	30.4.23 Total funds £
FIXED ASSETS			
Tangible assets	12	131	163
Social investments	13	<u>53,396</u>	<u>42,205</u>
		53,527	42,368
CURRENT ASSETS			
Stocks	14	322	322
Debtors	15	85	485
Cash at bank		<u>1,607,845</u>	<u>1,844,688</u>
		1,608,252	1,845,495
CREDITORS			
Amounts falling due within one year	16	(8,550)	(10,005)
		<u>1,599,702</u>	<u>1,835,490</u>
NET CURRENT ASSETS			
		1,653,229	1,877,858
TOTAL ASSETS LESS CURRENT LIABILITIES			
		<u>1,653,229</u>	<u>1,877,858</u>
NET ASSETS			
		<u>1,653,229</u>	<u>1,877,858</u>
FUNDS	17		
Unrestricted funds		<u>1,653,229</u>	<u>1,877,858</u>
TOTAL FUNDS		<u>1,653,229</u>	<u>1,877,858</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 24/02/2025 and were signed on its behalf by:



Mr J Whitworth - Trustee

**Notes to the Financial Statements
FOR THE YEAR ENDED 30 APRIL 2024**

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention, as modified by the revaluation of certain assets.

Financial reporting standard 102 - reduced disclosure exemptions

The charity has taken advantage of the following disclosure exemption in preparing these financial statements, as permitted by FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland':

- the requirements of Section 7 Statement of Cash Flows.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings - 20% on reducing balance

Social investments

Social investments comprise programme related investments which are measured at cost less impairment.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Pension costs and other post-retirement benefits

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Going concern

After reviewing the charities forecast and projections, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The charity therefore continues to adopt the going concern basis in preparing the financial statements.

JOINING JACK

Notes to the Financial Statements - continued FOR THE YEAR ENDED 30 APRIL 2024

2. DONATIONS AND LEGACIES

	30.4.24	30.4.23
	£	£
Donations	<u>238,372</u>	<u>92,281</u>

3. OTHER TRADING ACTIVITIES

	30.4.24	30.4.23
	£	£
Fundraising events	248,362	80,645
Merchandise sales	<u>1,803</u>	<u>730</u>
	<u>250,165</u>	<u>81,375</u>

4. INVESTMENT INCOME

	30.4.24	30.4.23
	£	£
Deposit account interest	<u>15,732</u>	<u>227</u>

5. RAISING FUNDS

Raising donations and legacies

	30.4.24	30.4.23
	£	£
Staff costs	61,418	61,757
Rent	2,400	2,400
Fundraising costs	18,385	2,516
Travel costs	1,618	2,164
Postage, stationery and sundry	3,313	1,838
Computer costs	7,918	3,460
Depreciation	<u>33</u>	<u>41</u>
	<u>95,085</u>	<u>74,176</u>

Other trading activities

	30.4.24	30.4.23
	£	£
Purchases	<u>105,981</u>	<u>63,162</u>
Aggregate amounts	<u>201,066</u>	<u>137,338</u>

JOINING JACK

Notes to the Financial Statements - continued FOR THE YEAR ENDED 30 APRIL 2024

6. CHARITABLE ACTIVITIES COSTS

Grant
funding of
activities
(see note
7)
£
530,581

Funding research

7. GRANTS PAYABLE

30.4.24	30.4.23
£	£
<u>530,581</u>	<u>486,124</u>

Funding research

The total grants paid to institutions during the year was as follows:

30.4.24	30.4.23
£	£
<u>530,581</u>	<u>486,124</u>

Duchenne UK Grant Call

8. SUPPORT COSTS

Governance
costs
£
7,518

Other resources expended

9. AUDITORS' REMUNERATION

30.4.24	30.4.23
£	£
<u>5,730</u>	<u>5,399</u>

Fees payable to the charity's auditors for the audit of the charity's financial statements

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 30 April 2024 nor for the year ended 30 April 2023.

Trustees' expenses

There were no trustees' expenses paid for the year ended 30 April 2024 nor for the year ended 30 April 2023.

JOINING JACK

Notes to the Financial Statements - continued FOR THE YEAR ENDED 30 APRIL 2024

11. Staff Costs

	30.4.24	30.4.23
	£	£
Wages and salaries	61,418	61,757
Other pension costs	<u>924</u>	<u>1,216</u>
	<u><u>62,342</u></u>	<u><u>62,973</u></u>

The average monthly number of employees during the year was as follows:

	30.4.24	30.4.23
Costs of generating voluntary income	2	2
Research and campaigning	<u>1</u>	<u>1</u>
	<u><u>3</u></u>	<u><u>3</u></u>

No employees received emoluments in excess of £60,000.

12. TANGIBLE FIXED ASSETS

	Fixtures and fittings £
COST	
At 1 May 2023 and 30 April 2024	<u>1,461</u>
DEPRECIATION	
At 1 May 2023	1,298
Charge for year	<u>32</u>
At 30 April 2024	<u>1,330</u>
NET BOOK VALUE	
At 30 April 2024	<u>131</u>
At 30 April 2023	<u><u>163</u></u>

JOINING JACK

Notes to the Financial Statements - continued FOR THE YEAR ENDED 30 APRIL 2024

13. SOCIAL INVESTMENTS

Joining Jack is a shareholder in Duchenne Research (UK) Investment Ltd [DRIL], a company incorporated in the UK as a company limited by shares on 9 December 2014.

Alex Johnson, one of the founders of Joining Jack, is a director of DRIL.

The purpose of DRIL is to invest in SOLID Biosciences. SOLID Biosciences undertakes gene therapy-based research into Duchenne Muscular Dystrophy and drug development and treatments in connection therewith. SOLID Biosciences is listed on Nasdaq.

In October 2022, SOLID Biosciences implemented a 1-for-15 reverse split of its common stock, resulting in the number of shares held by DRIL reducing from 520,477 to 34,698. As a result, the share price of SOLID Biosciences has increased in year ended 30th April 2024. Therefore, the market value of the investment in DRIL as at the balance sheet date shows a revaluation of £11,191 (2023: - £32,532 Impairment).

Further commentary regarding the charity's investment in DRIL is included in the financial review section of the Trustee's Report.

14. STOCKS

	30.4.24	30.4.23
	£	£
Stocks	<u>322</u>	<u>322</u>

15. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	30.4.24	30.4.23
	£	£
Gift Aid debtor	85	85
Prepayments	<u>-</u>	<u>400</u>
	<u>85</u>	<u>485</u>

16. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	30.4.24	30.4.23
	£	£
Trade creditors	-	1
Taxation and social security	(650)	112
Other creditors	<u>9,200</u>	<u>9,892</u>
	<u>8,550</u>	<u>10,005</u>

JOINING JACK

Notes to the Financial Statements - continued FOR THE YEAR ENDED 30 APRIL 2024

17. MOVEMENT IN FUNDS

	At 1.5.23 £	Net movement in funds £	At 30.4.24 £
Unrestricted funds			
General fund	1,877,858	(224,629)	1,653,229
TOTAL FUNDS	<u>1,877,858</u>	<u>(224,629)</u>	<u>1,653,229</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	504,269	(728,898)	(224,629)
TOTAL FUNDS	<u>504,269</u>	<u>(728,898)</u>	<u>(224,629)</u>

Comparatives for movement in funds

	At 1.5.22 £	Net movement in funds £	At 30.4.23 £
Unrestricted funds			
General fund	2,369,131	(491,273)	1,877,858
TOTAL FUNDS	<u>2,369,131</u>	<u>(491,273)</u>	<u>1,877,858</u>

JOINING JACK

Notes to the Financial Statements - continued FOR THE YEAR ENDED 30 APRIL 2024

17. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	173,883	(665,156)	(491,273)
TOTAL FUNDS	<u>173,883</u>	<u>(665,156)</u>	<u>(491,273)</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.5.22 £	Net movement in funds £	At 30.4.24 £
Unrestricted funds			
General fund	2,369,131	(715,902)	1,653,229
TOTAL FUNDS	<u>2,369,131</u>	<u>(715,902)</u>	<u>1,653,229</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	678,152	(1,394,054)	(715,902)
TOTAL FUNDS	<u>678,152</u>	<u>(1,394,054)</u>	<u>(715,902)</u>

18. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 30 April 2024.

JOINING JACK

Detailed Statement of Financial Activities FOR THE YEAR ENDED 30 APRIL 2024

	30.4.24 £	30.4.23 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	238,372	92,281
Other trading activities		
Fundraising events	248,362	80,645
Merchandise sales	<u>1,803</u>	<u>730</u>
	250,165	81,375
Investment income		
Deposit account interest	<u>15,732</u>	<u>227</u>
Total incoming resources	504,269	173,883
EXPENDITURE		
Raising donations and legacies		
Wages	61,418	61,757
Rent	2,400	2,400
Fundraising costs	18,385	2,516
Travel costs	1,618	2,164
Postage, stationery and sundry	3,313	1,838
Computer costs	7,918	3,460
Depreciation of fixtures and fittings	<u>33</u>	<u>41</u>
	95,085	74,176
Other trading activities		
Cost of events	105,981	63,162
Charitable activities		
Grants to institutions	530,581	486,124
Other		
Pensions	924	1,216
Impairment losses for intangible fixed assets	-	32,532
Impairment losses for tangible fixed assets	<u>(11,191)</u>	<u>-</u>
	(10,267)	33,748
Support costs		
Governance costs		
Auditors' remuneration	5,730	5,399
Accountancy and legal fees	<u>1,788</u>	<u>2,547</u>
	<u>7,518</u>	<u>7,946</u>
Total resources expended	<u>728,898</u>	<u>665,156</u>
Net expenditure	<u>(224,629)</u>	<u>(491,273)</u>

This page does not form part of the statutory financial statements

This page does not form part of the statutory financial statements

JOINING JACK

England & Wales - Charity number 1148156

Accounts

**Report of the Trustees and
Financial Statements
for the Year Ended 30 April 2023
for
JOINING JACK**

NRB
1st Floor Waterside House
Waterside Drive
Wigan
Lancashire
WN3 5AZ

JOINING JACK

Contents of the Financial Statements FOR THE YEAR ENDED 30 APRIL 2023

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 9
Report of the Independent Auditors	10 to 11
Statement of Financial Activities	12
Balance Sheet	13
Cash Flow Statement	14
Notes to the Cash Flow Statement	15
Notes to the Financial Statements	16 to 21
Detailed Statement of Financial Activities	22

JOINING JACK

Reference and Administrative Details FOR THE YEAR ENDED 30 APRIL 2023

Trustees	Mr J Whitworth Ms A Kent Mr K Radlinski
Principal address	c/o ADM Leisurewear Ltd Unit 1 Appleton Street Wigan Lancashire WN3 4BZ
Registered charity number	1148156
Auditors	NRB 1st Floor Waterside House Waterside Drive Wigan Lancashire WN3 5AZ

JOINING JACK

Report of the Trustees FOR THE YEAR ENDED 30 APRIL 2023

The trustees present their report with the financial statements of the charity for the year ended 30 April 2023. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Objectives and activities

Objectives and activities for the public benefit

The principal objective of the charity is to relieve the needs of sufferers of Duchenne Muscular Dystrophy (DMD), speed up treatments for all children and adults living with DMD by funding research into methods of treatment and a cure of the condition.

Objectives and activities

Significant activities

On 22 April 2016 Joining Jack joined forces with Duchenne UK, another parent-led charity formerly called The Duchenne Children's Trust, set up by Emily and Nick Crossley.

Joining Jack remains a separate charity and holds stand-alone fundraising events but now shares a research strategy, scientific advisory board and Director of Research with Duchenne UK.

Research

An end of year project report dated December 2023, from Alessandra Gaeta, Director of Research for Duchenne UK & Joining Jack, (Joining Jack & DUK Research Portfolio End of Year report 2023 – pages 7-8) provides an end-of-year progress update on all the projects funded by Joining Jack in the Duchenne UK portfolio.

This is an overview of new funding opportunities in the pipeline. The report covers active projects and projects that have completed in 2023. Historical projects which have closed in 2022 and before are not included. For each funded project, a status, update on progress and update on funding is included.

Our research strategy has now expanded to include six key elements to it, all of which are integral to accelerating and advancing research. Funding the research is the first crucial step. But on its own it isn't enough. We need to look at the overall landscape of research and drug development, and our strategy has been developed to reflect this.

1) Fund and accelerate research for early stage clinical trials

Our approach is 100% focused on advancing research and getting treatments into clinic and to patients as quickly as possible. Working alongside co-founder of Duchenne UK Emily Crossley, our co-founder, Alex Johnson, actively seeks out projects and potential therapies which could benefit the current generation of patients. We run an international grant call. We invest globally in basic science, translational research and clinical trials.

2) Facilitate and accelerate research

We are committed to accelerating the pace of research, ensuring that we remove potential obstacles and roadblocks that lie in the path of drug development. It is vital that the research we fund has the potential to translate into clinical trials, and so we fund the doctors, nurses and physiotherapists necessary to conduct trials in the UK. We created and expanded the DMD Hub which has the ambition that every child born with Duchenne in the UK has the opportunity to take part in research. We also support and encourage national and international collaboration to allow researchers and clinicians to collaborate and progress research. We are proud to support the Treat-NMD network and their bi-annual TACT meetings to review potential clinical trials for Duchenne muscular dystrophy.

3) Implementation of the Standards of Care (SoC) in the UK

The updated SoC were published in The Lancet of Neurology in 2018. They are ambitious and significantly advance on the 2010 version. While this is welcomed by families and clinicians, it presents challenges at a national level where the health care systems need to increase or change provision, and in many cases increase resources in order to deliver the fully updated SoC. We have launched a new project DMD Care UK to tackle this issue. The project will ensure everyone in the UK living with Duchenne has access to the best care.

4) Work alongside industry

We work with industry, advising on clinical trial designs. We have advised on the protocols of a number of different trials. We work with Project Hercules and their industry partners to help collect the data they need to aid reimbursement decisions of drugs.

5) Continued engagement with regulators and policy makers

We are engaging with policy makers and regulators on many issues, from campaigning for Early Access to Medicines to engaging with the Health Technology Appraisal system.

6) Collaborate with families and charities globally

We work with families to empower them to get the best access to care and treatments for their children. We work with Duchenne UK to stage free Patient Information days across the UK, and in February, 2024 we will stage our first international conference in London. Alex Johnson also sits on the board of the World Duchenne Organization to ensure we collaborate with charities internationally.

Our Scientific Advisory Board (SAB) is a fundamental part of our project review process - and ensures our supporters' donations are being invested in the right projects to advance the DMD field. For several years now, we have been proud to work with the following experts:

Dr John Bourke, Newcastle University, UK
Prof Annemieke Aartsma-Rus, Leiden University Medical Centre, Netherlands
Dr Eric Hoffman, ReveraGen Biopharma, Canada
Prof Dame Kay Davies, University of Oxford, UK
Steve Winder, University of Sheffield, UK
Dirk Fischer, University Children's Hospital Basel, Switzerland
Dr Dada Pisconti, Stonybrook University, USA

These are all researchers at the top of their field and are generous enough to share their expertise and knowledge, regardless of the huge demands on their time.

Given the expanding remit of our work and the variety of projects which we support, we are delighted to announce that four new researchers will be joining our SAB:

Frank Robertson, Whizz-Kidz, UK
Dr Manuela Corti, University of Florida, USA
Dr Valeria Ricotti, DiNAQOR, UK
Dr Olivier Dorchies, University of Geneva, Switzerland

Volunteers

The charity has an incredible ever-growing army of volunteers who enable the staging of the three main flagship fundraising multi-participant events.

An existing database of more than 150 names alongside local running and cycling clubs and Army Cadets, are called upon to help with pre-event preparation (goodie bag packing and race/ride packs) and on the day to hand out medals, water, refreshments marshal routes and support runners/riders at the start and finish.

Our volunteer database continues to grow to help us create and stage the four mass participation events.

Achievement and performance

Fundraising activities

Run Wigan Festival

2017 saw us launch two new flagship fundraising events the first of which was the Run Wigan Festival in March featuring a Half Marathon, a 5k and Family Mile run. The event celebrated its third year in 2019 when a fourth distance was introduced to the event in the shape of a 10 Miler. The race was a sell-out.

The 4th Run Wigan Festival in 2020, was cancelled with less than a week to go, due to COVID and eventually staged virtually and a date was never officially set for the 2021 event due to the ongoing restrictions and a third national Lockdown, meaning we were unable to stage the event for two years. The Run Wigan Festival returned in 2022 and included 329 deferred entries from 2020, while all runners who had taken part in the Virtual Run Wigan Festival of 2020 were offered a 25% discount for their support throughout the ongoing cancellations and to maintain engagement with the charity's established event network. This did have an effect on fundraising and did mean that the event could have potentially run at a loss but the Trustees, along with the co-founders, and Race Director were in agreement that it was important to stage the event and honour the deferrals and discount codes to maintain the charity and the event's reputation. This would be the final event to be affected financially as a knock-on effect of COVID and Lockdowns and turned around £10,000 profit.

The Run Wigan Festival moved to a new home in 2023 following in the footsteps of the Wigan 10k and relocating to Mesnes Park. This involved a few tweaks to the routes and a bigger section of the flagship HM route taking place along the canal requiring increased volunteer and steward numbers.

NUMBERS: 708 Half Marathon, 572 5k, 294 (& 150 on day) Family Mile TOTAL: 1,724

Under the continued Title Sponsorship of HW Moon Toyota Wigan, the event raised £13,500, a worthy total given previous years' efforts, an increase on the 2022 total. With numbers attending mass participation events continuing on an upward trend during two extremely difficult years of events when many smaller events and businesses associated with them have fallen by the wayside, this is encouraging.

The date for the 2024 Run Wigan Festival has been set for Sunday, March 17, and we are delighted to report that we have already surpassed our 2023 runner numbers weeks ahead of registration closing.

Wigan Bike Ride

After three years of taking part as a team in organised Bike Rides, the charity made the decision to stage its first ever organised bike ride on July 22nd 2017 under the Title Sponsorship of Develop UK and featured a 50 Mile main ride on open roads and a 5 Mile family ride on closed roads along the Wigan 10k route.

The 4th Bike Ride in 2020 was cancelled due to the ongoing pandemic and took place as a virtual event with 278 riders participating with support from all over the north-west and UK and from across the world.

The charity's first mass participation flagship fundraising since the pandemic event was the 5th Bike Ride in 2021 at a change of venue due to availability and slightly smaller numbers just before COVID guidelines were fully relaxed so social distancing was maintained outdoors. New Hardcore and Highway routes were introduced for the 50 mile ride.

The 2022 Bike Ride returned to its original home of Mesnes Park and the welcome return of the 5 Mile Family Ride - the first time this had been staged since 2019 and in 2023, the 7th Wigan Bike Ride took place in soaring temperatures.

NUMBERS: 210 Main 85 Family TOTAL: 295

Under the continued Title Sponsorship of Develop UK, the 2023 event raised £18,500, numbers slightly down on the previous year but a small increase in fundraising. A total of £168,000 raised from the Bike Ride to date

The date for the 2024 8th Wigan Bike Ride has been set for Sunday, June 23 when we are looking to introduce a 25 Mile route for intermediary riders.

JY3Peaks

The JY3Peaks took place in July when we teamed up with two other charities, Gand Aid and Lifting Louis. We had 68 walkers in total including 20 for Joining Jack. The day ran smoothly (apart from the typical 3 peaks unpredictable weather) and was a success with the vast majority of our walkers crossing the finish line. Together team JJ raised £6500.

We are currently looking at dates in May and July for the 2024 event and potentially teaming up with Gand Aid again.

Wigan 10k

The 10th Wigan 10k took place on Sunday, September 11, 2022, at a brand new Event HQ and a new Start/Finish over at Mesnes Park. Due to the ongoing works in the town centre, the decision was taken to relocate to the park and invited vendors to provide food and drink options for runners. There was also a return to live entertainment following the race - the first time since COVID.

First staged in 2013 as Joining Jack's inaugural flagship fundraising event, the 10th Wigan 10k coincided with 10 years of Joining Jack. Final numbers were disappointing which we believe, having spoken to our Event Partners and other Race organisers, is an ongoing consequence of COVID, and the cost of living crisis. However, the new Start/Finish, along with food and drink vendors at Event HQ proved to be an overwhelming success.

NUMBERS: 1,900 10k 265 (& 150 on day) Family Mile TOTAL: 2,315

The event raised £37,000 - a significant increase on the past two years which is encouraging for our events based fundraising and we hope to continue that trend with further increases in 2024.

The date for the 2024 Wigan 10k has been set for Sunday, September 1. Given the promising numbers that took part in 2023, we have targeted 2,000 - 2,500 runners taking us closer to totals achieved before the pandemic.

Emirates Dubai Sevens

The 2020 event was cancelled due to the global pandemic. The charity did look to take part in the 2021 and paid an agreed 20% of the registrations fees but, with concerns over players being able to travel from other countries, an enquiry was made into switching to the Over 45s category which could accommodate UK-based players who are more known to the Johnson family. However, this proved impractical as the category already had the allotted number of entries.

With uncertainty still surrounding player availability in 2022, the charity had not registered an interest and paid a deposit for the 2022 event. When a place became available quite close to the date of the event taking place, the charity was unable to secure the sponsorship from Title Sponsors Emirates to cover the costs of the Team's flights. This would have meant a significant increase in costs and a deficit in fundraising and the decision was made not to take the last minute place. Following a four-year absence the charity returned to the competition with a host of new faces from both codes of rugby representing Team JJ.

Alex worked tirelessly to secure more than £100,000 in sponsorship. We enjoyed some great coverage ahead of the trip thanks to local news and TV which increases the profile of the Duchenne community. Over in Dubai a successful Golf Day, Gents Brunch and auction, further media coverage and a great run in the competition saw the team eventually lose out on the Plate Final but not before gaining a host of new followers and supporters for the year ahead.

A fantastic £200,000 was raised with income still coming in from merchandise sales and player shirt auctions.

The charity's participation in the Emirates Dubai Sevens involves a brand new challenge and pressures on the Johnson family but also provides a global audience in the fight against Duchenne and increased revenue streams which will fund promising projects in 2024. Alex and Andy, along with the Trustees are considering the participation in the 2024 event.

£275,000 TOTAL FOR 2023 FLAGSHIP FUNDRAISING EVENTS

Fundraising 2023 Summary

The charity relies heavily on our own flagship events and supporters taking part in mass participation events. Many if not all of these were cancelled in 2020 and in the first half of 2021 due to COVID-19 Coronavirus. This had a significant effect on the charity's income both in 2020 and 2021 and has also affected overall fundraising income in 2022 with a continued knock-on effect of deferrals and discounted entries in the Run Wigan Festival 2022, our first event of the year. With the cost of living crisis also having an effect on numbers taking part, the overall fundraising total for 2022 was around 25% of what the charity has previously raised. However, 2023 looks to be an indication of a significant turning point for events and fundraising. The return to higher numbers taking part and the record-breaking success of the charity's return to the Dubai 7s has returned a healthy fundraising total for 2023 which we hope will continue in 2024.

Other fundraising initiatives 2023

FUNDRAISING

The Joining Jack team have been promoting the charity's flagship events along with individual supporters and team contributions and donations. We also promote our own merchandise through Ebay for Charity Shop which provides a steady source of income. The charity has also had continued support from sponsors, event partners and supporters throughout the year including two new Associate Sponsors for the running and third sponsors on board for the Wigan 10k in 2024, which is positive support going forward. The success of the Dubai 7s trip and media coverage along with awareness and engagement on our social media channels, we are confident that the fight to end Duchenne is continuing to garner support and grow stronger connections with the Team JJ brand alongside our charitable objective.

CAMPAIGNS, COMMUNITY WORK & RECOGNITION

At the start of 2023, Jack and his family were invited by Wigan Council to attend the unveiling of Star in the Wigan Walk of Fame to mark a decade of the charity creating awareness for Duchenne and bringing the town together to get fit.

Alex, Jack's mum, and one of the charity's co-founders, has also been recognised for her work in the Duchenne Community with an OBE which she received at Windsor Castle in January.

IMPACT REPORT

Our battle against Duchenne muscular dystrophy is now 12 years old. We have included an update on how the work of Joining Jack alongside our partners Duchenne UK, is making significant progress in many different areas. This includes:

- The approval of Vamorolone by the FDA and EMA. This is the first drug for all people with DMD, which Duchenne UK played a key role in developing.
- While our Project HERCULES is helping support the health technology assessment of Vamorolone, which is currently being appraised by NICE.
- We launched a new project to drive better care for nutrition and weight management in DMD.
- The third version of our SMART Suit prototype has been developed and is being tested.
- Our psychosocial programme has developed a referral pathway for children with DMD and patients are now being referred to it.
- Our DMD Care UK programme published a new bone health guide for people with DMD and their families.
- Our DMDhome digital platform has entered the validation phase. DMDhome uses video capture and computer vision

- analysis to measure limb function in DMD. The study will aim to validate this new approach for use in clinical trials and potentially in the approval of new medicines for DMD.
- Our Central Recruitment Database has moved on from the pilot stage. Every commercial DMD trial opened in the UK since its establishment has recruited patients using it.
- We are undertaking extensive research with young people with DMD to completely rethink how wheelchairs can help them live their lives.

The full Impact Report 2023 is attached - Duchenne UK Impact Report 2023.

Funding and research decisions

We have listed in the table on pages 7 and 8, a list of the grants we have awarded to date. We have colour-coded the grants to show how we are supporting the whole therapeutic development pipeline. Joining Jack is committed to ensuring that as much as possible of our funds goes to developing research into a treatment or a cure for Duchenne Muscular Dystrophy.

We are particularly focused on transitional research, research that takes potential therapeutics out of laboratories and into clinical trials. Working closely with our partner charity Duchenne UK, our trusted team of scientific advisors, patient advisory board and trustees, we have made major decisions on how to spend the funds raised. The grants that we have been awarded have led to breakthroughs that are changing the therapeutic landscape for the Duchenne community.

DMD Care UK = Red
Basic Research = Yellow
Preclinical Research = Green
Clinical Trial Support = Blue
Clinical Trials = Orange

Project Name	Research/Institution or Company	Project Status	Total Grant Award
DMD Care Neuropsychiatrist	University of Glasgow	Complete	£75,000
Antifibrotic/antiadipogenic drug Fibrogenesis	Newcastle University	Complete	£32,688
Hydrotherapy Clinical Trial	Dr De ~~Google~~ , Royal Preston Hospital	Started	£118,000
Immunology Grant Call Award	Professor ~~Kapnebovina~~ Nagaraju, Binghamton, the State University of New York	Started	£1,000
Biomarker Trial	Duke University	Started	£20,000
Dream Chair development	Whizz ~~Kidz~~	Ongoing	£50,000
DMD Care UK	Newcastle University	Ongoing	£140,000
Immunology Grant	University of Florida	Ongoing	£185,000
Splint Trial	Newcastle University	Started	£10,000
Stem Cells	University of Minnesota	Started	£140,000
Vitamin B3	Leiden University	Started	£10,000
Tackling fibrosis and muscle regeneration	Agada Biosciences	Started	£25,000
Repurposing Drugs	Dr Olivier ~~Dorchies~~ , University of Geneva	Started	£25,000
Testosterone extension	~~Prof~~ Volker Straub, University of Newcastle	Started	£10,000
Adult NMCCC	Dr Chiara Marini- ~~Bettolo~~ , University of Newcastle	Ongoing	£10,000
Open label extension study for Tamoxifen	Dr Dirk Fischer, University Children's Hospital Basel	Pending	£230,000.00
Taurine	Dr Peter Arthur, Senior Lecturer, The University of Western Australia	Ongoing	£50,000
Fibrosis	Dr Lee ~~Borthwich~~ , University of Newcastle	Ongoing	£10,000
New ways of delivering Gene Therapy	EVOX Therapeutics	Ongoing	£200,000
Understanding heart disease in DMD	Dr John Bourke, Freeman Hospital	Ongoing	£67,000.00
Investigating soy products as a treatment for DMD	Prof Steve Winder, University of Sheffield	Ongoing	£30,500
Preclinical study of the combination of tamoxifen, L-citrulline and metformin	Dr Olivier ~~Dorchies~~ , University of Geneva	Ongoing	£200,000
Use of Elastase Inhibitors to Treat DMD	Dr Addolorata ~~Pisconti~~ , University of Liverpool	Ongoing	£36,365.00
Duchenne Clinical Research Nurse	Alder Hey Children's Hospital, Liverpool	Ongoing	£32,106.50
F2 Neuromuscular Clinical Research Doctor	Alder Hey Children's Hospital, Liverpool	Complete	£30,513
ST4 Neuromuscular Clinical Research Doctor	Alder Hey Children's Hospital, Liverpool	Complete	£127,121.00
Tamoxifen Clinical Trial	Dr Dirk Fischer, University Children's Hospital Basel	Ongoing	£194,996.99
Tamoxifen Project Manager	Dr Dirk Fischer, University Children's Hospital Basel	Ongoing	£97,000
TREAT-NMD DMD Co-Ordinator Role	University of Newcastle	Ongoing	£78,832.66
Physiotherapist	Alder Hey Children's Hospital, Liverpool	Complete	£45,960.00
Duchenne Clinical Trial Nurse	Royal Victoria Infirmary, Newcastle	Complete	£22,500
Co-Funded Lectureship for a Clinical Research Lectureship/ Senior Lectureship in Duchenne Muscular Dystrophy	Dr ~~Guelieri~~ , University of Newcastle	Ongoing	£35,714.30
Assessing the preclinical therapeutic impact of cannabidiol for DMD	Dr Keith Foster, The University of Reading	Complete	£6213.09
The Duchenne Forum, Supporting 8 basic research projects	Muscular Dystrophy Campaign	Complete	£55,346.00

Project Name	Research/Institution or Company	Project Status	Total Grant Award
Gene therapy	Solid GT, Boston, USA	Complete	\$1,666,666.66
VBP-15, Phase 1 Clinical Trial	Reverigen BioPharma Inc, USA	Complete	\$400,000.00
DMD Heart Protection Study	Dr Spinty, Alder Hey	Complete	£14,000
Phase1/2 Clinical trial of HT-100	Akashi Therapeutics, USA	Complete	\$100,000
Developing biomarkers for Utrophin Modulators	Summit Corporation, Oxford, UK	Complete	£100,000

Financial review

Financial position

Results for the year are shown in the Statement of Financial Activities on page 12.

Investment policy and objectives

The charity's investment policy is to retain all available funds on deposit to give sufficient liquidity to meet ongoing day-to-day needs.

Financial review

Reserves policy

The Trustees have determined that a minimum unrestricted reserve of approximately £10,000 is required to ensure the ongoing operations of the charity. The charity does not require a significant restricted reserve because it does not currently have material fixed costs. The charity recognises it may be appropriate to allow the reserve to fluctuate as a result of short-term cash inflows and outflows and to ensure the funding of projects to which it is contractually committed.

Future plans

Our future plans

In the coming year we plan to:

- Through DMD Care UK continue to implement the new Standards of Care and also launch a Transition grant call.
- Provide education to families on research and care.
- Provide psychological support to families and patients living with Duchenne through the pathway we develop.
- Continue to develop the Duchenne Hub.
- Create research opportunities for Adults with Duchenne by developing new outcome measures.
- Work to overcome the immunological issues preventing delivery of gene therapy.
- Advance research into the methods of delivery of gene therapy for Duchenne patients.
- Bring the Dream Chair to market.
- Develop new outcome measures for clinical trials.
- Help optimise clinical trial designs.
- Fund the next development phase of the SMART Suit arm assist product.

Structure, governance and management

Constitution

The charity is governed by its Declaration of Trust dated 28 February 2012, as amended by Deed dated 16 July 2012.

Recruitment and appointment of new trustees

The trustees who have served during the year are set out on page 1. The trustees are appointed by the committee.

Organisational structure

The trustees meet on a regular basis to discuss the work and development of the organisation. The Scientific Advisory Board reviews applications for funding received from the pharmaceuticals sector and reports its findings back to the Board of Trustees.

Induction and training of new trustees

New trustees are given guidance provided by the committee which covers such items as roles and responsibilities, legal obligations under charity law, organisational structures and decision making processes, business planning and understanding financial information. The induction process also involves new trustees meeting key employees and other trustees. Trustees are encouraged to attend appropriate training events which will facilitate their understanding of their role and meet their individual training needs.

Statement of trustees' responsibilities

The trustees are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales, the Charities Act 2011, Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the charity and the surplus or deficit of the charity for that period. In preparing these statements, the trustees are required to:

- Select suitable accounting policies and apply them consistently;
- Make judgements and estimates that are reasonable and prudent;
- Follow applicable accounting standards, subject to any material departures disclosed and explained in the financial statements;
- Prepare the financial statements on an ongoing basis unless it is inappropriate to assume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

27/02/2024

Approved by order of the board of trustees on and signed on its behalf by:



.....
Mr K Radlinski - Trustee

Report of the Independent Auditors to the Trustees of Joining Jack

Opinion

We have audited the financial statements of Joining Jack (the 'charity') for the year ended 30 April 2023 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 30 April 2023 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Report of the Independent Auditors to the Trustees of Joining Jack

Our responsibilities for the audit of the financial statements

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

We identified areas of laws and regulations that could reasonably be expected to have a material effect on the financial statements from our general commercial and sector experience, through discussion with the directors and other management (as required by auditing standards), and from inspection of the charity's regulatory and legal correspondence and discussed with the directors and other management the policies and procedures regarding compliance with laws and regulations. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit.

The potential effect of these laws and regulations on the financial statements varies considerably.

Firstly, the charity is subject to laws and regulations that directly affect the financial statements including financial reporting legislation (including related companies legislation), distributable profits legislation, pensions legislation and taxation legislation, and we assessed the extent of compliance with these laws and regulations as part of our procedures the related financial statement items.

Owing to the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Cathy Rogers

Catherine Rogers BSc FCA (Senior Statutory Auditor)
NRB
1st Floor Waterside House
Waterside Drive
Wigan
Lancashire
WN3 5AZ

27/02/2024

Date:

JOINING JACK

Statement of Financial Activities FOR THE YEAR ENDED 30 APRIL 2023

		30.4.23 Unrestricted fund £	30.4.22 Total funds £
INCOME AND ENDOWMENTS FROM	Notes		
Donations and legacies	3	92,281	90,623
Other trading activities	4	81,375	83,175
Investment income	5	227	15
Total		<u>173,883</u>	<u>173,813</u>
EXPENDITURE ON			
Raising funds	6	137,338	124,781
Charitable activities	7		
Funding research		486,124	112,688
Other		<u>41,694</u>	<u>522,347</u>
Total		<u>665,156</u>	<u>759,816</u>
NET INCOME/(EXPENDITURE)		(491,273)	(586,003)
RECONCILIATION OF FUNDS			
Total funds brought forward		<u>2,369,131</u>	<u>2,955,134</u>
TOTAL FUNDS CARRIED FORWARD		<u><u>1,877,858</u></u>	<u><u>2,369,131</u></u>

The notes form part of these financial statements


JOINING JACK

Balance Sheet 30 APRIL 2023

	Notes	30.4.23 Unrestricted fund £	30.4.22 Total funds £
FIXED ASSETS			
Tangible assets	13	163	204
Social investments	14	<u>42,205</u>	<u>74,737</u>
		42,368	74,941
CURRENT ASSETS			
Stocks	15	322	322
Debtors	16	485	485
Cash at bank		<u>1,844,688</u>	<u>2,297,808</u>
		1,845,495	2,298,615
CREDITORS			
Amounts falling due within one year	17	(10,005)	(4,425)
		<u>1,835,490</u>	<u>2,294,190</u>
NET CURRENT ASSETS			
		1,877,858	2,369,131
TOTAL ASSETS LESS CURRENT LIABILITIES			
		<u>1,877,858</u>	<u>2,369,131</u>
NET ASSETS			
		<u>1,877,858</u>	<u>2,369,131</u>
FUNDS	18		
Unrestricted funds		<u>1,877,858</u>	<u>2,369,131</u>
TOTAL FUNDS		<u>1,877,858</u>	<u>2,369,131</u>

27/02/2024

The financial statements were approved by the Board of Trustees and authorised for issue on and were signed on its behalf by:



Mr J Whitworth - Trustee

JOINING JACK

Cash Flow Statement FOR THE YEAR ENDED 30 APRIL 2023

	Notes	30.4.23 £	30.4.22 £
Cash flows from operating activities			
Cash generated from operations	1	<u>(453,347)</u>	<u>(69,838)</u>
Net cash used in operating activities		<u>(453,347)</u>	<u>(69,838)</u>
Cash flows from investing activities			
Interest received		<u>227</u>	<u>15</u>
Net cash provided by investing activities		<u>227</u>	<u>15</u>
		<u> </u>	<u> </u>
Change in cash and cash equivalents in the reporting period		(453,120)	(69,823)
Cash and cash equivalents at the beginning of the reporting period		<u>2,297,808</u>	<u>2,367,631</u>
Cash and cash equivalents at the end of the reporting period		<u><u>1,844,688</u></u>	<u><u>2,297,808</u></u>

The notes form part of these financial statements

JOINING JACK

Notes to the Cash Flow Statement FOR THE YEAR ENDED 30 APRIL 2023

1. RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES

	30.4.23	30.4.22
	£	£
Net expenditure for the reporting period (as per the Statement of Financial Activities)	(491,273)	(586,003)
Adjustments for:		
Depreciation charges	41	51
Interest received	(227)	(15)
Losses/(gains) on investments	32,532	517,523
Increase in debtors	-	(400)
Increase/(decrease) in creditors	5,580	(994)
Net cash used in operations	<u>(453,347)</u>	<u>(69,838)</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.5.22	Cash flow	At 30.4.23
	£	£	£
Net cash			
Cash at bank	<u>2,297,808</u>	<u>(453,120)</u>	<u>1,844,688</u>
	<u>2,297,808</u>	<u>(453,120)</u>	<u>1,844,688</u>
Total	<u>2,297,808</u>	<u>(453,120)</u>	<u>1,844,688</u>

JOINING JACK

Notes to the Financial Statements FOR THE YEAR ENDED 30 APRIL 2023

1. STATUTORY INFORMATION

Joining Jack is a charitable company, limited by guarantee and has no share capital and is registered in England and Wales. The company's registered number and registered office address can be found in the Report of the Trustees.

The presentation currency of the financial statements is Pound Sterling (£).

2. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 20% on reducing balance
-----------------------	---------------------------

Social investments

Social investments comprise programme related investments which are measured at cost less impairment.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Pension costs and other post-retirement benefits

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

Going concern

After reviewing the company's forecast and projections, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The charity therefore continues to adopt the going concern basis in preparing the financial statements.

JOINING JACK

Notes to the Financial Statements - continued FOR THE YEAR ENDED 30 APRIL 2023

3. DONATIONS AND LEGACIES

	30.4.23	30.4.22
	£	£
Donations	<u>92,281</u>	<u>90,623</u>

4. OTHER TRADING ACTIVITIES

	30.4.23	30.4.22
	£	£
Fundraising events	80,645	82,871
Merchandise sales	<u>730</u>	<u>304</u>
	<u>81,375</u>	<u>83,175</u>

5. INVESTMENT INCOME

	30.4.23	30.4.22
	£	£
Deposit account interest	<u>227</u>	<u>15</u>

6. RAISING FUNDS

Raising donations and legacies

	30.4.23	30.4.22
	£	£
Staff costs	61,757	54,611
Rent	2,400	2,400
Fundraising costs	2,516	10,489
Travel costs	2,164	1,412
Postage, stationery and sundry	1,838	840
Computer costs	3,460	2,535
Depreciation	41	51
Government Grants	<u>-</u>	<u>(8,169)</u>
	<u>74,176</u>	<u>64,169</u>

Other trading activities

	30.4.23	30.4.22
	£	£
Purchases	63,162	60,932
Support costs	<u>-</u>	<u>(320)</u>
	<u>63,162</u>	<u>60,612</u>

Aggregate amounts	<u>137,338</u>	<u>124,781</u>
-------------------	----------------	----------------

JOINING JACK

Notes to the Financial Statements - continued FOR THE YEAR ENDED 30 APRIL 2023

7. CHARITABLE ACTIVITIES COSTS

		Grant funding of activities (see note 8) £
Funding research		<u>486,124</u>

8. GRANTS PAYABLE

	30.4.23	30.4.22
	£	£
Funding research	<u>486,124</u>	<u>112,688</u>

The total grants paid to institutions during the year was as follows:

	30.4.23	30.4.22
	£	£
Duchenne UK Grant Call	<u>486,124</u>	<u>112,688</u>

9. SUPPORT COSTS

	Governance costs £
Other resources expended	<u>7,946</u>

10. AUDITORS' REMUNERATION

	30.4.23	30.4.22
	£	£
Fees payable to the charity's auditors for the audit of the charity's financial statements	<u>5,399</u>	<u>3,502</u>

11. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 30 April 2023 nor for the year ended 30 April 2022.

Trustees' expenses

There were no trustees' expenses paid for the year ended 30 April 2023 nor for the year ended 30 April 2022.

JOINING JACK

Notes to the Financial Statements - continued FOR THE YEAR ENDED 30 APRIL 2023

12. STAFF COSTS

	30.4.23	30.4.22
	£	£
Wages and salaries	61,757	54,611
Other pension costs	<u>1,216</u>	<u>1,002</u>
	<u>62,973</u>	<u>55,613</u>

The average monthly number of employees during the year was as follows:

	30.4.23	30.4.22
Costs of generating voluntary income	2	2
Research and campaigning	<u>1</u>	<u>1</u>
	<u>3</u>	<u>3</u>

No employees received emoluments in excess of £60,000.

13. TANGIBLE FIXED ASSETS

	Fixtures and fittings £
COST	
At 1 May 2022 and 30 April 2023	<u>1,461</u>
DEPRECIATION	
At 1 May 2022	1,257
Charge for year	<u>41</u>
At 30 April 2023	<u>1,298</u>
NET BOOK VALUE	
At 30 April 2023	<u>163</u>
At 30 April 2022	<u>204</u>

14. SOCIAL INVESTMENTS

Joining Jack is a shareholder in Duchenne Research (UK) Investment Ltd [DRIL], a company incorporated in the UK as a company limited by shares on 9 December 2014.

Alex Johnson, one of the founders of Joining Jack, is a director of DRIL.

The purpose of DRIL is to invest in SOLID Biosciences. SOLID Biosciences undertakes gene therapy-based research into Duchenne Muscular Dystrophy and drug development and treatments in connection therewith. SOLID Biosciences is listed on Nasdaq.

In October 2022, SOLID Biosciences implemented a 1-for-15 reverse split of its common stock, resulting in the number of shares held by DRIL reducing from 520,477 to 34,698. At 30 April 2023, the share price of SOLID Biosciences had increased due to the 1-for-15 reverse split of its common stock. As a result, the market value of the investment in DRIL as at the balance sheet date is shows a revaluation of £32,532 (2022 - £517,523) compared to the original cost of £1,073,399.

JOINING JACK

Notes to the Financial Statements - continued FOR THE YEAR ENDED 30 APRIL 2023

15. STOCKS

	30.4.23	30.4.22
	£	£
Stocks	<u>322</u>	<u>322</u>

16. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	30.4.23	30.4.22
	£	£
Gift Aid debtor	85	85
Prepayments	<u>400</u>	<u>400</u>
	<u>485</u>	<u>485</u>

17. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	30.4.23	30.4.22
	£	£
Taxation and social security	113	1,270
Other creditors	<u>9,892</u>	<u>3,155</u>
	<u>10,005</u>	<u>4,425</u>

18. MOVEMENT IN FUNDS

	At 1.5.22	Net movement in funds	At 30.4.23
	£	£	£
Unrestricted funds			
General fund	2,369,131	(491,273)	1,877,858
	<u>2,369,131</u>	<u>(491,273)</u>	<u>1,877,858</u>

Net movement in funds, included in the above are as follows:

	Incoming resources	Resources expended	Movement in funds
	£	£	£
Unrestricted funds			
General fund	173,883	(665,156)	(491,273)
	<u>173,883</u>	<u>(665,156)</u>	<u>(491,273)</u>

JOINING JACK

Notes to the Financial Statements - continued FOR THE YEAR ENDED 30 APRIL 2023

18. MOVEMENT IN FUNDS - continued

Comparatives for movement in funds

	At 1.5.21 £	Net movement in funds £	At 30.4.22 £
Unrestricted funds			
General fund	2,955,134	(586,003)	2,369,131
TOTAL FUNDS	<u>2,955,134</u>	<u>(586,003)</u>	<u>2,369,131</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	173,813	(759,816)	(586,003)
TOTAL FUNDS	<u>173,813</u>	<u>(759,816)</u>	<u>(586,003)</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.5.21 £	Net movement in funds £	At 30.4.23 £
Unrestricted funds			
General fund	2,955,134	(1,077,276)	1,877,858
TOTAL FUNDS	<u>2,955,134</u>	<u>(1,077,276)</u>	<u>1,877,858</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	347,696	(1,424,972)	(1,077,276)
TOTAL FUNDS	<u>347,696</u>	<u>(1,424,972)</u>	<u>(1,077,276)</u>

JOINING JACK

**Notes to the Financial Statements - continued
FOR THE YEAR ENDED 30 APRIL 2023**

19. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 30 April 2023.

JOINING JACK

Detailed Statement of Financial Activities FOR THE YEAR ENDED 30 APRIL 2023

	30.4.23 £	30.4.22 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	92,281	90,623
Other trading activities		
Fundraising events	80,645	82,871
Merchandise sales	<u>730</u>	<u>304</u>
	81,375	83,175
Investment income		
Deposit account interest	<u>227</u>	<u>15</u>
Total incoming resources	173,883	173,813
EXPENDITURE		
Raising donations and legacies		
Wages	61,757	54,611
Rent	2,400	2,400
Fundraising costs	2,516	10,489
Travel costs	2,164	1,412
Postage, stationery and sundry	1,838	840
Computer costs	3,460	2,535
Depreciation of fixtures and fittings	41	51
Government Grants	<u>-</u>	<u>(8,169)</u>
	74,176	64,169
Other trading activities		
Cost of events	63,162	60,932
Charitable activities		
Grants to institutions	486,124	112,688
Other		
Pensions	1,216	1,002
Impairment losses for intangible fixed assets	<u>32,532</u>	<u>517,523</u>
	33,748	518,525
Support costs		
Governance costs		
Auditors' remuneration	5,399	3,502
Accountancy and legal fees	<u>2,547</u>	<u>-</u>
	<u>7,946</u>	<u>3,502</u>
Total resources expended	<u>665,156</u>	<u>759,816</u>
Net expenditure	<u>(491,273)</u>	<u>(586,003)</u>

This page does not form part of the statutory financial statements

JOINING JACK

England & Wales - Charity number 1148156

Accounts

**REPORT OF THE TRUSTEES AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2022
FOR
JOINING JACK**

NRB
1st Floor Waterside House
Waterside Drive
Wigan
Lancashire
WN3 5AZ

JOINING JACK

CONTENTS OF THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2022

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 9
Report of the Independent Auditors	10 to 11
Statement of Financial Activities	12
Balance Sheet	13
Cash Flow Statement	14
Notes to the Cash Flow Statement	15
Notes to the Financial Statements	17 to 22
Detailed Statement of Financial Activities	23

JOINING JACK

REFERENCE AND ADMINISTRATIVE DETAILS FOR THE YEAR ENDED 30 APRIL 2022

Trustees	Mr J Whitworth Ms A Kent Mr K Radlinski
Principal address	c/o ADM Leisurewear Ltd Unit 1 Appleton Street Wigan Lancashire WN3 4BZ
Registered charity number	1148156
Auditors	NRB 1st Floor Waterside House Waterside Drive Wigan Lancashire WN3 5AZ

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2022

The trustees present their report with the financial statements of the charity for the year ended 30 April 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Objectives and activities

Objectives and activities for the public benefit

The principal objective of the charity is to relieve the needs of sufferers of Duchenne Muscular Dystrophy (DMD), speed up treatments for all children and adults living with DMD by funding research into methods of treatment and a cure of the condition.

Significant activities

On 22 April 2016 Joining Jack joined forces with Duchenne UK, another parent-led charity formerly called The Duchenne Children's Trust, set up by Emily and Nick Crossley.

Joining Jack remains a separate charity and holds stand-alone fundraising events but now shares a research strategy, scientific advisory board and Director of Research with Duchenne UK.

Research

An end of year project report, dated December 2022, from Alessandra Gaeta, Director of Research for Duchenne UK & Joining Jack, (JJ End of Year Project Report-DUK Dec 2022 - attached) provides an end-of-year progress update on all the projects funded by Joining Jack in the Duchenne UK portfolio. This is an overview of new funding opportunities in the pipeline. The report covers active projects and projects that have completed in 2022. Historical projects which have closed in 2021 and before are not included. For each funded project, a status, update on progress and update on funding is included.

Our research strategy has now expanded to include six key elements to it, all of which are integral to accelerating and advancing research. Funding the research is the first crucial step. But on its own it isn't enough. We need to look at the overall landscape of research and drug development, and our strategy has been developed to reflect this.

1) Fund and accelerate research for early stage clinical trials

Our approach is 100% focused on advancing research and getting treatments into clinic and to patients as quickly as possible. Working alongside co-founder of Duchenne UK Emily Crossley, our co-founder, Alex Johnson, actively seeks out projects and potential therapies which could benefit the current generation of patients. We run an international grant call. We invest globally in basic science, translational research and clinical trials.

2) Facilitate and accelerate research

We are committed to accelerating the pace of research, ensuring that we remove potential obstacles and roadblocks that lie in the path of drug development. It is vital that the research we fund has the potential to translate into clinical trials, and so we fund the doctors, nurses and physiotherapists necessary to conduct trials in the UK. We created and expanded the DMD Hub which has the ambition that every child born with Duchenne in the UK has the opportunity to take part in research. We also support and encourage national and international collaboration to allow researchers and clinicians to collaborate and progress research. We are proud to support the Treat-NMD network and their bi-annual TACT meetings to review potential clinical trials for Duchenne muscular dystrophy.

3) Implementation of the Standards of Care (SoC) in the UK

The updated SoC were published in The Lancet of Neurology in 2018. They are ambitious and significantly advance on the 2010 version. While this is welcomed by families and clinicians, it presents challenges at a national level where the health care systems need to increase or change provision, and in many cases increase resources in order to deliver the fully updated SoC. We have launched a new project DMD Care UK to tackle this issue. The project will ensure everyone in the UK living with Duchenne has access to the best care.

4) Work alongside industry

We work with industry, advising on clinical trial designs. We have advised on the protocols of a number of different trials. We work with Project Hercules and their industry partners to help collect the data they need to aid reimbursement decisions of drugs.

5) Continued engagement with regulators and policy makers

We are engaging with policy makers and regulators on many issues, from campaigning for Early Access to Medicines to engaging with the Health Technology Appraisal system.

6) Collaborate with families and charities globally

We work with families to empower them to get the best access to care and treatments for their children. As a result of COVID-19 we could not hold our free patient information days. We decided to work with Duchenne UK to hold 14 free patient information

webinars that have been watched by 300 people. Alex Johnson sits on the board of the World Duchenne Organization to ensure we collaborate with charities internationally.

Our Scientific Advisory Board (SAB) is a fundamental part of our project review process - and ensures our supporters' donations are being invested in the right projects to advance the DMD field. For several years now, we have been proud to work with the following experts:

Dr John Bourke, Newcastle University, UK
Prof Annemieke Aartsma-Rus, Leiden University Medical Centre, Netherlands
Dr Eric Hoffman, ReveraGen Biopharma, Canada
Prof Dame Kay Davies, University of Oxford, UK
Steve Winder, University of Sheffield, UK
Dirk Fischer, University Children's Hospital Basel, Switzerland
Dr Dada Pisconti, Stonybrook University, USA

These are all researchers at the top of their field and are generous enough to share their expertise and knowledge, regardless of the huge demands on their time.

Given the expanding remit of our work and the variety of projects which we support, we are delighted to announce that four new researchers will be joining our SAB:

Frank Robertson, Whizz-Kidz, UK
Dr Manuela Corti, University of Florida, USA
Dr Valeria Ricotti, DiNAQOR, UK
Dr Olivier Dorchies, University of Geneva, Switzerland

Volunteers

The charity has an incredible ever-growing army of volunteers who enable the staging of the three main flagship fundraising multi-participant events.

An existing database of more than 150 names alongside local running and cycling clubs and Army Cadets, are called upon to help with pre-event preparation (goodie bag packing and race/ride packs) and on the day to hand out medals, water, refreshments marshal routes and support runners/riders at the start and finish.

Although in smaller numbers due to COVID measures, our volunteers continued to do this when events returned in the second half of 2021 and returned in full force in 2022 as events began to get back to normal with all restrictions lifted.

Achievement and performance

Fundraising activities

Run Wigan Festival

2017 saw us launch two new flagship fundraising events the first of which was the Run Wigan Festival in March featuring a Half Marathon, a 5k and Family Mile run. The event celebrated its third year in 2019 and, after the disappointment of the 2018 Half Marathon cancellation due to weather conditions and runner safety, and a fall in registered runners for the Main Race, a fourth distance was introduced to the event in the shape of a 10 Miler. The race was a sell-out.

After the 4th Run Wigan Festival, due to take place on March 22, 2020, was cancelled with less than a week to go, the first of our events to be called off at the start of the first National Lockdown, the event eventually staged virtually with runners having their medals posted out or deferring their place to 2021. 1,500 runners took part virtually and the event managed to raise just over £28,000.

A date was never officially set for the 2021 event due to the ongoing restrictions and a third national Lockdown, meaning we were unable to stage the event for two years.

The Run Wigan Festival finally returned on March 20, 2022 and included 329 runners who had deferred their entries from back in 2020, while all runners who had taken part in the Virtual Run Wigan Festival of 2020 were offered a 25% discount to register as a gesture of goodwill for their support throughout the ongoing cancellations and to maintain engagement with the charity's established event network.

This did have an effect on fundraising and did mean that the event could have potentially run at a loss but the Trustees, along with co-founders, Alex and Andy Johnson, and the Race Director, Matt Johnson, were in agreement that it was important to stage the event and honour the deferrals and discount codes to maintain the charity and the event's reputation. This would be the final event to be affected financially as a knock on effect of COVID and Lockdowns

NUMBERS: 845 Half Marathon 293 10 Miler 608 5k 348 (& 150 on day) Family Mile TOTAL: 2,200

Under the continued Title Sponsorship of HW Moon Toyota Wigan, the event raised £10,000, a worthy total which should be considered a success, producing a profit despite all the costs/discounts hanging over from 2020, and the concerns as to whether the event may run at a loss.

The date for the 2023 Run Wigan Festival has been set for Sunday, March 18.

Wigan Bike Ride

After three years of taking part as a team in organised Bike Rides, the charity made the decision to stage its first ever organised bike ride. This took place on July 22nd 2017 under the Title Sponsorship of Develop UK and featured a 50 Mile main ride on open roads through Wigan and Lancashire, and a 5 Mile family ride on closed roads along the Wigan 10k route. It was an unprecedented success and on Sunday, June 30, 2019, the charity staged the third Wigan Bike Ride and raised a record-breaking total.

The 4th Bike Ride in 2020 was cancelled due to the ongoing pandemic and took place as a virtual event with 278 riders participating with support from all over the north-west and UK and from across the world including Australia, America, Chile and the UAE. Riders completed their 50 miles and were sent a Joining Jack JJ the Duchenne Destroyer medal and special edition Virtual Wigan Bike Ride T-shirt. The event raised more than £10,000.

The charity staged its first mass participation flagship fundraising since the pandemic event with the 5th Bike Ride in 2021 at a change of venue due to availability and slightly smaller numbers just before COVID guidelines were fully relaxed so social distancing was maintained outdoors. New Hardcore and Highway routes were introduced for the 50 mile ride with £17,000 raised.

The 2022 Bike Ride returned to its original home of Mesnes Park on June 19, with the 50 Mile Hardcore and Highway routes remaining (slightly tweaked for the new venue) and the welcome return of the 5 Mile Family Ride - the first time this had been staged since 2019.

NUMBERS: 234 Main 94 Family TOTAL: 328

Under the continued Title Sponsorship of Develop UK, the 2022 event £16,000 raised. A total of £150,000 raised from the Bike Ride to date

The date for the 2023 7th Wigan Bike Ride has been set for Sunday, June 11.

Wigan 10k

The 10th Wigan 10k took place on Sunday, September 11, at a brand new Event HQ and a new Start/Finish over art Mesnes Park. Due to the ongoing works in the town centre, the decision was taken to relocate to the park and invited vendors to provide food and drink options for runners. There was also a return to live entertainment following the race - the first time since COVID.

First staged in 2013 as Joining Jack's inaugural flagship fundraising event, the 10th Wigan 10k coincided with 10 years of Joining Jack. There was almost a last minute major hiccup as the event came under threat of cancellation due to the passing of the queen 72 hours before. With the backing of the council, the decision was taken for the event to go ahead featuring a minute's silence and the playing of the National Anthem.

Final numbers were disappointing which we believe, having spoken to our Event Partners and other Race organisers, is an ongoing consequence of COVID, and the cost of living crisis.

However, the new Start/Finish, along with food and drink vendors at Event HQ proved to be an overwhelming success.

NUMBERS: 1,394 10k 251 (& 150 on day) Family Mile TOTAL: 1,900

The event raised £17,000 - lower than previous years.

The date for the 2023 Wigan 10k has been set for Sunday, September 3.

£47,000 TOTAL FOR 2022 FLAGSHIP FUNDRAISING MASS PARTICIPATION EVENTS

Emirates Dubai Sevens

The 2020 event was cancelled due to the global pandemic. The charity did look to take part in the 2021 and paid an agreed 20% of the registrations fees but, with concerns over players being able to travel from other countries, an enquiry was made into switching to the Over 45s category which could accommodate UK-based players who are more known to the Johnson family. However, this proved impractical as the category already had the allotted number of entries.

With uncertainty still surrounding player availability in 2022, the charity had not registered an interest and paid a deposit for the 2022 event. When a place became available quite close to the date of the event taking place, the charity was unable to secure the sponsorship from Title Sponsors Emirates to cover the costs of the Team's flights. This would have meant a significant increase in costs and a deficit in fundraising and the decision was made not to take the last minute place.

Having spoken with the trustees and Emirates, Alex and Andy are confident of support from sponsors, players and ambassadors, for the charity and the JJ Legends team to return to the competition in 2023.

JJ3Peaks, Supporter Fundraising & Community Fundraising events

The biggest ever JJY3 Peaks had been planned for Saturday, September 6, 2020. This was also cancelled due to the global pandemic. We were delighted therefore when the JJY3P returned in 2022 after a 4-year break on May 7 with 25 walkers including Alex and Jonathan Whitworth (Trustee) taking on the Yorkshire 3 peaks in brilliant weather conditions. In vibrant orange t-shirts, the team created awareness on mountain tops with JJ salutes at every summit. Together the team raised £4,000.

The date for the 2023 JJY3P has been set for Saturday, July 8.

Fundraising 2022 Summary

The charity relies heavily on our own flagship events and supporters taking part in mass participation events. Many if not all of these were cancelled in 2020 and in the first half of 2021 due to COVID-19 Coronavirus. This has had a significant effect on the charity's income both in 2020 and 2021 and has also affected overall fundraising income in 2022 with a continued knock-on effect of deferrals and discounted entries in the Run Wigan Festival 2022, our first event of the year. With the cost of living crisis continuing to have an effect on numbers taking part in all mass participation events.

The overall fundraising total for 2022 was around 25% of what the charity has previously raised from the four flagship events with the Emirates Dubai Sevens has previously raised £90,000 - £100,000 and the three home-based events having raised closed to £100,000. This shows the impact of COVID, supporter engagement and the cost of living crisis which has meant a significant reduction in fundraising for between 2020 and 2022.

Other fundraising initiatives 2022

FUNDRAISING

The Joining Jack team have been working on a Team JJ merchandise campaign through the charity's Ebay shop and also a Team JJ advent calendar to build awareness. The merchandise is mainly stock which has been accumulated over the past three years so there is no additional cost and has raised £700+.

The charity has also had continued support from sponsors, event partners and supporters throughout the continued restrictions and limited fundraising opportunities, maintaining a strong connection with the Team JJ brand and continuing to raise awareness of our overall charitable objective.

10 YEARS OF JOINING JACK CAMPAIGN

2022 marked 10 years since Joining Jack was created by Alex and Andy Johnson, just a few months after their son, Jack, was diagnosed with Duchenne Muscular Dystrophy. In 2022 we worked with Bradley Clarke from Social Feed Media to create 10 Videos of 10 of the charity's biggest achievements over the past 10 years.

Jack was also invited to deliver the match ball at the final of the Disability Rugby League World Cup Final.

Jack was also invited to take to the pitch for the National Anthem with England Rugby Union captain Owen Farrell to mark his 100 caps in the team's match with the All Blacks.

LETTER FROM FOUNDERS

Our battle against Duchenne muscular dystrophy is now 10 years old and we have been reflecting on that milestone throughout the year and some of our achievements over the past decade.

In 2011, when Jack was first diagnosed, we were broken by a diagnosis that had robbed our son of his future. By forming Joining Jack in 2012, we hoped to claw some of that future back.

In 2016, after many collaborations including investing in research, lobbying to parliament, and discussing parental care for our sons, we joined forces with another powerful parent-led charity, the Duchenne Children's Trust, to form Duchenne UK.

As Joining Jack and Duchenne UK, we have worked tirelessly to achieve so much more than we could have ever imagined. None of this could have been achieved without you. We are so grateful.

Since 2012 we have attempted to change the landscape for Jack and ALL boys living with Duchenne. We have created four flagship fundraising events, involving more than 30,000 runners, riders, walkers, climbers, wheelchair users, pram pushers, friends, family, schools, community groups and even a deep sea diver!

Together with our participants, supporters, volunteers, partners and sponsors, we have raised more than £2.5 million which we have invested in research, clinical posts and trials, care packages and every potential channel of hope to better treatments that we can possibly imagine.

Ten years ago, we were told gene therapy would not be ready in Jack's lifetime. We disagreed. We were seed funders of Solid Biosciences, a start-up established to pursue this new technology, and boys are being dosed with gene therapy in this country now.

We invested in Vamorolone - a drug that promised just that. The trials have been successful - we are now working with the company to help gain regulatory approval.

We wanted more trials to come to the UK and more boys to have the chance to take part in new treatments. We conceived and funded the DMD Hub - a network of sites across the country meaning more trials are happening than ever before. An achievement that seems all the more remarkable given that trials in the rest of the UK are falling.

We were horrified to find there were potential treatments out there - but no-one willing to pay for them. We helped change the law to allow medicines to be approved more quickly - and formed Project HERCULES, a unique collaboration between patients, academics and drug companies to ensure more treatments get NHS funding.

We learnt that patients with DMD were dying too young because they were not getting the right care. DMD Care UK is establishing best practice across all the disciplines - and fighting to ensure all medical professionals and parents know exactly what children and adults with DMD need.

And we saw technological advances ignore the needs of our children. We are investing in a Smart Suit and a Dream Chair to make sure the innovation that has inspired the smart phone and the electric car also delivers for the disabled community.

We are 10 years old, but feel we are just beginning. Please stay with us in our fight to end Duchenne.
You can read more about the impact and progress our work - thanks to your support - alongside Duchenne UK in 2022

<https://joiningjack.org/media/pj1iir0d/duchenne-uk-impact-report-2022-10-years-digital.pdf>

Achievement and performance

Funding and research decisions

We have listed in the table below a list of the grants we have awarded to date. We have colour-coded the grants to show how we are supporting the whole therapeutic development pipeline. Joining Jack is committed to ensuring that as much as possible of our funds goes to developing research into a treatment or a cure for Duchenne Muscular Dystrophy.

We are particularly focused on transitional research, research that takes potential therapeutics out of laboratories and into clinical trials. Working closely with our partner charity Duchenne UK, our trusted team of scientific advisors, patient advisory board and trustees, we have made major decisions on how to spend the funds raised. The grants that we have awarded have led to breakthroughs that are changing the therapeutic landscape for the Duchenne community.

DMD Care UK = Red
Basic Research = Yellow
Preclinical Research = Green
Clinical Trial Support = Blue
Clinical Trials = Orange

Project Name	Research/Institution or Company	Project Status	Total Grant Award
DMD Care Neuropsychiatrist	University of Glasgow	Complete	£75,000
Antifibrotic/antiadipogenic drug Fibrogenesis	Newcastle University	Complete	£32,688
Hydrotherapy Clinical Trial	Dr De Geode, Royal Preston Hospital	Started	£118,000
Immunology Grant Call Award	Professor Kanneboyina Nagaraju, Binghamton, the State University of New York	Started	£1,000
Biomarker Trial	Duke University	Started	£20,000
Dream Chair development	Whizz Kidz	Ongoing	£50,000
DMD Care UK	Newcastle University	Ongoing	£140,000
Immunology Grant	University of Florida	Ongoing	£185,000
Splint Trial	Newcastle University	Started	£10,000
Stem Cells	University of Minnesota	Started	£140,000
Vitamin B3	Leiden University	Started	£10,000
Tackling fibrosis and muscle regeneration	Agada Biosciences	Started	£25,000
Repurposing Drugs	Dr Olivier Dorchies, University of Geneva	Started	£25,000
Testosterone extension	Prf Volker Straub, University of Newcastle	Started	£10,000
Adult NMCCC	Dr Chiara Marini-Bettolo, University of Newcastle	Ongoing	£10,000
Open label extension study for Tamoxifen	Dr Dirk Fischer, University Children's Hospital Basel	Pending	£230,000.00
Taurine	Dr Peter Arthur, Senior Lecturer, The University of Western Australia	Ongoing	£50,000
Fibrosis	Dr Lee Borthwich, University of Newcastle	Ongoing	£10,000
New ways of delivering Gene Therapy	EVOX Therapeutics	Ongoing	£200,000
Understanding heart disease in DMD	Dr John Bourke, Freeman Hospital	Ongoing	£67,000.00
Investigating soy products as a treatment for DMD	Prof Steve Winder, University of Sheffield	Ongoing	£30,500
Preclinical study of the combination of tamoxifen, L-citrulline and metformin	Dr Olivier Dorchies, University of Geneva	Ongoing	£200,000
Use of Elastase Inhibitors to Treat DMD	Dr Addolorata Pisconti, University of Liverpool	Ongoing	£36,365.00
Duchenne Clinical Research Nurse	Alder Hey Children's Hospital, Liverpool	Ongoing	£32,106.50
F2 Neuromuscular Clinical Research Doctor	Alder Hey Children's Hospital, Liverpool	Complete	£30,513
ST4 Neuromuscular Clinical Research Doctor	Alder Hey Children's Hospital, Liverpool	Complete	£127,121.00
Tamoxifen Clinical Trial	Dr Dirk Fischer, University Children's Hospital Basel	Ongoing	£194,996.99
Tamoxifen Project Manager	Dr Dirk Fischer, University Children's Hospital Basel	Ongoing	£97,000
TREAT-NMD DMD Co-Ordinator Role	University of Newcastle	Ongoing	£78,832.66
Physiotherapist	Alder Hey Children's Hospital, Liverpool	Complete	£45,960.00
Duchenne Clinical Trial Nurse	Royal Victoria Infirmary, Newcastle	Complete	£22,500
Co-Funded Lectureship for a Clinical Research Lectureship/ Senior Lectureship in Duchenne Muscular Dystrophy	Dr Guglieri, University of Newcastle	Ongoing	£35,714.30
Assessing the preclinical therapeutic impact of cannabidiol for DMD	Dr Keith Foster, The University of Reading	Complete	£6213.09
The Duchenne Forum, Supporting 8 basic research projects	Muscular Dystrophy Campaign	Complete	£55,346.00

Gene therapy	Solid GT, Boston, USA	Complete	\$1,666,666.66
VBP-15, Phase 1 Clinical Trial	Reveragen BioPharma Inc, USA	Complete	\$400,000.00
DMD Heart Protection Study	Dr Spinty, Alder Hey	Complete	£14,000
Phase1/2 Clinical trial of HT-100	Akashi Therapeutics, USA	Complete	\$100,000
Developing biomarkers for Utrophin Modulators	Summit Corporation, Oxford, UK	Complete	£100,000

Financial review

Financial position

Results for the year are shown in the Statement of Financial Activities on page 12.

Investment policy and objectives

The charity's investment policy is to retain all available funds on deposit to give sufficient liquidity to meet ongoing day-to-day needs.

Reserves policy

The Trustees have determined that a minimum unrestricted reserve of approximately £10,000 is required to ensure the ongoing operations of the charity. The charity does not require a significant restricted reserve because it does not currently have material fixed costs. The charity recognises it may be appropriate to allow the reserve to fluctuate as a result of short-term cash inflows and outflows and to ensure the funding of projects to which it is contractually committed.

Solid Bioscience

Due to a reverse stock split in October 2022, DRIL shareholding has been diluted to 34,698 which makes a significant difference. At the exchange rate ruling this gives a value of £231,029.

Valuation at the end of April 22 was:

05/02/2022	\$8.2496
04/29/2022	\$8.3996
04/28/2022	\$8.8181
04/27/2022	\$9.6505

Valuation in \$ = 34698 X \$8.3996 = \$291449. at the exchange rate ruling gives a value of £231,029.

Future plans

Our future plans

In the coming year we plan to:

- Through DMD Care UK continue to implement the new Standards of Care for patients in the UK.
- Provide education to families on research and care.
- Provide psychological support to families and patients living with Duchenne through the pathway we develop.
- Continue to develop the Duchenne Hub.
- Create research opportunities for Adults with Duchenne by developing new outcome measures.
- Work to overcome the immunological issues preventing delivery of gene therapy.
- Advance research into the methods of delivery of gene therapy for Duchenne patients.
- Bring the Dream Chair to market.
- Develop new outcome measures for clinical trials.
- Help optimise clinical trial designs

Structure, governance and management

Constitution

The charity is governed by its Declaration of Trust dated 28 February 2012, as amended by Deed dated 16 July 2012.

Recruitment and appointment of new trustees

The trustees who have served during the year are set out on page 1. The trustees are appointed by the committee.

Organisational structure

The trustees meet on a regular basis to discuss the work and development of the organisation. The Scientific Advisory Board reviews applications for funding received from the pharmaceuticals sector and reports its findings back to the Board of Trustees.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2022

Structure, governance and management

Induction and training of new trustees

New trustees are given guidance provided by the committee which covers such items as roles and responsibilities, legal obligations under charity law, organisational structures and decision making processes, business planning and understanding financial information. The induction process also involves new trustees meeting key employees and other trustees. Trustees are encouraged to attend appropriate training events which will facilitate their understanding of their role and meet their individual training needs.

Statement of trustees' responsibilities

The trustees are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales, the Charities Act 2011, Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.


The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial period which give a true and fair view of the state of affairs of the charity and the surplus or deficit of the charity for that period. In preparing these statements, the trustees are required to:

- Select suitable accounting policies and apply them consistently;
- Make judgements and estimates that are reasonable and prudent;
- Follow applicable accounting standards, subject to any material departures disclosed and explained in the financial statements;
- Prepare the financial statements on an ongoing basis unless it is inappropriate to assume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the board of trustees on 28 February 2023 and signed on its behalf by:



Mr K Radlinski - Trustee

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF JOINING JACK

Opinion

We have audited the financial statements of Joining Jack (the 'charity') for the year ended 30 April 2022 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 30 April 2022 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

**REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF
JOINING JACK**

Our responsibilities for the audit of the financial statements

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

We identified areas of laws and regulations that could reasonably be expected to have a material effect on the financial statements from our general commercial and sector experience, through discussion with the directors and other management (as required by auditing standards), and from inspection of the charity's regulatory and legal correspondence and discussed with the directors and other management the policies and procedures regarding compliance with laws and regulations. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit.

The potential effect of these laws and regulations on the financial statements varies considerably.

Firstly, the charity is subject to laws and regulations that directly affect the financial statements including financial reporting legislation (including related companies legislation), distributable profits legislation, pensions legislation and taxation legislation, and we assessed the extent of compliance with these laws and regulations as part of our procedures the related financial statement items.

Owing to the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.



NRB
1st Floor Waterside House
Waterside Drive
Wigan
Lancashire
WN3 5AZ

Date: 28 February 2023

JOINING JACK

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 30 APRIL 2022

		30.4.22 Unrestricted fund £	30.4.21 Total funds £
INCOME AND ENDOWMENTS FROM	Notes		
Donations and legacies	2	90,623	44,590
Other trading activities	3	83,175	142,423
Investment income	4	15	155
Total		<u>173,813</u>	<u>187,168</u>
 EXPENDITURE ON			
Raising funds	5	124,781	68,323
Charitable activities	6		
Funding research		112,688	434,323
Other		<u>522,347</u>	<u>(277,073)</u>
Total		<u>759,816</u>	<u>225,573</u>
 NET INCOME/(EXPENDITURE)		(586,003)	(38,405)
 RECONCILIATION OF FUNDS			
Total funds brought forward		2,955,134	2,993,539
 TOTAL FUNDS CARRIED FORWARD		<u><u>2,369,131</u></u>	<u><u>2,955,134</u></u>

The notes form part of these financial statements

JOINING JACK

BALANCE SHEET 30 APRIL 2022

		30.4.22 Unrestricted fund £	30.4.21 Total funds £
FIXED ASSETS	Notes		
Tangible assets	12	204	255
Social investments	13	<u>74,737</u>	<u>592,260</u>
		74,941	592,515
CURRENT ASSETS			
Stocks	14	322	322
Debtors	15	485	85
Cash at bank		<u>2,297,808</u>	<u>2,367,631</u>
		2,298,615	2,368,038
CREDITORS			
Amounts falling due within one year	16	(4,425)	(5,419)
		<u>2,294,190</u>	<u>2,362,619</u>
NET CURRENT ASSETS			
		2,369,131	2,955,134
NET ASSETS		<u>2,369,131</u>	<u>2,955,134</u>
FUNDS	17		
Unrestricted funds		<u>2,369,131</u>	<u>2,955,134</u>
TOTAL FUNDS		<u>2,369,131</u>	<u>2,955,134</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 28 February 2023 and were signed on its behalf by:


Mr J Whitworth - Trustee

JOINING JACK

CASH FLOW STATEMENT FOR THE YEAR ENDED 30 APRIL 2022

	Notes	30.4.22 £	30.4.21 £
Cash flows from operating activities			
Cash generated from operations	1	<u>(69,838)</u>	<u>(318,706)</u>
Net cash used in operating activities		<u>(69,838)</u>	<u>(41,633)</u>
Cash flows from investing activities			
Interest received		<u>15</u>	<u>155</u>
Net cash provided by investing activities		<u>15</u>	<u>155</u>
		<u> </u>	<u> </u>
Change in cash and cash equivalents in the reporting period		<u>(69,823)</u>	<u>(318,551)</u>
Cash and cash equivalents at the beginning of the reporting period		<u>2,367,631</u>	<u>2,686,183</u>
Cash and cash equivalents at the end of the reporting period		<u><u>2,297,808</u></u>	<u><u>2,367,631</u></u>

The notes form part of these financial statements

JOINING JACK

NOTES TO THE CASH FLOW STATEMENT FOR THE YEAR ENDED 30 APRIL 2022

1. RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES

	30.4.22 £	30.4.21 £
Net expenditure for the reporting period (as per the Statement of Financial Activities)	(586,003)	(38,405)
Adjustments for:		
Depreciation charges	51	64
Interest received	(15)	(155)
Losses/(gains) on investments	517,523	(277,073)
Increase in debtors	(400)	-
Decrease in creditors	(994)	(3,137)
Net cash used in operations	<u>(69,838)</u>	<u>(318,706)</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.5.21 £	Cash flow £	At 30.4.22 £
Net cash			
Cash at bank	<u>2,367,631</u>	<u>(69,823)</u>	<u>2,297,808</u>
	<u>2,367,631</u>	<u>(69,823)</u>	<u>2,297,808</u>
Total	<u>2,367,631</u>	<u>(69,823)</u>	<u>2,297,808</u>

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2022

Basis of preparing the financial statements

Income

Expenditure

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings - 20% on reducing balance

Social investments

Social investments comprise programme related investments which are measured at cost less impairment.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Pension costs and other post-retirement benefits

The charity operates a defined contribution pension scheme. Contributions payable to the charity's pension scheme are charged to the Statement of Financial Activities in the period to which they relate.

2. DONATIONS AND LEGACIES

	30.4.22	30.4.21
	£	£
Donations	90,623	44,590

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2022

3. OTHER TRADING ACTIVITIES

	30.4.22	30.4.21
	£	£
Fundraising events	82,871	142,423
Merchandise sales	304	-
	<u>83,175</u>	<u>142,423</u>

4. INVESTMENT INCOME

	30.4.22	30.4.21
	£	£
Deposit account interest	<u>15</u>	<u>155</u>

5. RAISING FUNDS

Raising donations and legacies

	30.4.22	30.4.21
	£	£
Staff costs	54,611	53,725
Rent	2,400	2,400
Fundraising costs	10,489	17,762
Travel costs	1,412	-
Postage, stationery and sundry	840	864
Computer costs	2,535	1,986
Depreciation	51	64
Government Grants	(8,169)	(12,197)
Support costs	<u>-</u>	<u>4,630</u>
	<u>64,169</u>	<u>69,234</u>

6. CHARITABLE ACTIVITIES COSTS

	Grant funding of activities (see note 7) £
Funding research	<u>112,688</u>

7. GRANTS PAYABLE

	30.4.22	30.4.21
	£	£
Funding research	<u>112,688</u>	<u>434,323</u>

The total grants paid to institutions during the year was as follows:

	30.4.22	30.4.21
	£	£
Duchenne UK Grant Call	<u>112,688</u>	<u>434,323</u>

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2022

8. SUPPORT COSTS

	Governance costs £
Other trading activities	(320)
Other resources expended	<u>3,822</u>
	<u>3,502</u>

Support costs, included in the above, are as follows:

	30.4.22	30.4.21
	Other trading activities £	Other resources expended £
Auditors' remuneration	(320)	3,822
Auditors' remuneration for non audit work	-	-
Accountancy and legal fees	-	-
	<u>(320)</u>	<u>3,822</u>
	<u>3,502</u>	<u>4,630</u>

9. AUDITORS' REMUNERATION

	30.4.22 £	30.4.21 £
Fees payable to the charity's auditors for the audit of the charity's financial statements	3,502	4,090
Auditors' remuneration for non audit work	<u>-</u>	<u>360</u>

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 30 April 2022 nor for the year ended 30 April 2021.

Trustees' expenses

There were no trustees' expenses paid for the year ended 30 April 2022 nor for the year ended 30 April 2021.

11. STAFF COSTS

	30.4.22 £	30.4.21 £
Wages and salaries	54,611	53,725
Other pension costs	<u>1,002</u>	<u>-</u>
	<u>55,613</u>	<u>53,725</u>

The average monthly number of employees during the year was as follows:

	30.4.22	30.4.21
Costs of generating voluntary income	2	2
Research and campaigning	<u>1</u>	<u>1</u>
	<u>3</u>	<u>3</u>

No employees received emoluments in excess of £60,000.

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2022

12. TANGIBLE FIXED ASSETS

	Fixtures and fittings £
COST	
At 1 May 2021 and 30 April 2022	<u>1,461</u>
DEPRECIATION	
At 1 May 2021	1,206
Charge for year	<u>51</u>
At 30 April 2022	<u>1,257</u>
NET BOOK VALUE	
At 30 April 2022	<u>204</u>
At 30 April 2021	<u>255</u>

13. SOCIAL INVESTMENTS

Joining Jack is a shareholder in Duchenne Research (UK) Investment Ltd [DRIL], a company incorporated in the UK as a company limited by shares on 9 December 2014.

Alex Johnson, one of the founders of Joining Jack, is a director of DRIL.

The purpose of DRIL is to invest in SOLID Biosciences. SOLID Biosciences undertakes gene therapy-based research into Duchenne Muscular Dystrophy and drug development and treatments in connection therewith. SOLID Biosciences is listed on Nasdaq.

At 30 April 2022 the share price of SOLID Biosciences had reduced as a result of research projects led by the company being put on hold given the implications the global pandemic. As a result, the market value of the investment in DRIL as at the balance sheet date is shows a revaluation of £517,523 (2021 - £277,073) compared to the original cost of £1,073,399.

Further commentary regarding the charity's investment in DRIL is included in the financial review section of the Trustee's Report.

14. STOCKS

	30.4.22 £	30.4.21 £
Stocks	<u>322</u>	<u>322</u>

15. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	30.4.22 £	30.4.21 £
Gift Aid debtor	85	85
Prepayments	<u>400</u>	<u>-</u>
	<u>485</u>	<u>85</u>

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2022

16. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	30.4.22 £	30.4.21 £
Trade creditors	-	1,999
Taxation and social security	1,270	-
Other creditors	<u>3,155</u>	<u>3,420</u>
	<u>4,425</u>	<u>5,419</u>

17. MOVEMENT IN FUNDS

	At 1.5.21 £	Net movement in funds £	At 30.4.22 £
Unrestricted funds			
General fund	2,955,134	(586,003)	2,369,131
	<u>2,955,134</u>	<u>(586,003)</u>	<u>2,369,131</u>
TOTAL FUNDS	<u>2,955,134</u>	<u>(586,003)</u>	<u>2,369,131</u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	173,813	(759,816)	(586,003)
	<u>173,813</u>	<u>(759,816)</u>	<u>(586,003)</u>
TOTAL FUNDS	<u>173,813</u>	<u>(759,816)</u>	<u>(586,003)</u>

Comparatives for movement in funds

	At 1.5.20 £	Net movement in funds £	At 30.4.21 £
Unrestricted funds			
General fund	2,993,539	(38,405)	2,955,134
	<u>2,993,539</u>	<u>(38,405)</u>	<u>2,955,134</u>
TOTAL FUNDS	<u>2,993,539</u>	<u>(38,405)</u>	<u>2,955,134</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	187,168	(225,573)	(38,405)
	<u>187,168</u>	<u>(225,573)</u>	<u>(38,405)</u>
TOTAL FUNDS	<u>187,168</u>	<u>(225,573)</u>	<u>(38,405)</u>

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2022

17. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.5.20 £	Net movement in funds £	At 30.4.22 £
Unrestricted funds			
General fund	2,993,539	(624,408)	2,369,131
TOTAL FUNDS	<u>2,993,539</u>	<u>(624,408)</u>	<u>2,369,131</u>

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	360,981	(985,389)	(624,408)
TOTAL FUNDS	<u>360,981</u>	<u>(985,389)</u>	<u>(624,408)</u>

18. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 30 April 2022.

JOINING JACK

DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 30 APRIL 2022

	30.4.22 £	30.4.21 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	90,623	44,590
Other trading activities		
Fundraising events	82,871	142,423
Merchandise sales	304	-
	83,175	142,423
Investment income		
Deposit account interest	15	155
Total incoming resources	173,813	187,168
EXPENDITURE		
Raising donations and legacies		
Wages	54,611	53,725
Rent	2,400	2,400
Fundraising costs	10,489	17,762
Travel costs	1,412	-
Postage, stationery and sundry	840	864
Computer costs	2,535	1,986
Depreciation of fixtures and fittings	51	64
Government Grants	(8,169)	(12,197)
	64,169	64,604
Other trading activities		
Cost of events	60,932	(911)
Charitable activities		
Grants to institutions	112,688	434,323
Other		
Pensions	1,002	-
Impairment losses for intangible fixed assets	517,523	(277,073)
	518,525	(277,073)
Support costs		
Governance costs		
Auditors' remuneration	3,502	4,090
Auditors' remuneration for non audit work	-	360
Accountancy and legal fees	-	180
	3,502	4,630
Total resources expended	759,816	225,573
Net expenditure	(586,003)	(38,405)

This page does not form part of the statutory financial statements

JOINING JACK

England & Wales - Charity number 1148156

Accounts

**REPORT OF THE TRUSTEES AND
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2021
FOR
JOINING JACK**

NR Barton
1st Floor Waterside House
Waterside Drive
Wigan
Lancashire
WN3 5AZ

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

The trustees present their report with the financial statements of the charity for the year ended 30 April 2021. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Objectives and activities

Objectives and activities for the public benefit

The principal objective of the charity is to relieve the needs of sufferers of Duchenne Muscular Dystrophy (DMD), speed up treatments for all children and adults living with DMD by funding research into methods of treatment and a cure of the condition.

Significant activities

On 22 April 2016 Joining Jack joined forces with Duchenne UK, another parent-led charity formerly called The Duchenne Children's Trust, set up by Emily and Nick Crossley.

Joining Jack remains a separate charity and holds stand-alone fundraising events but now shares a research strategy, scientific advisory board and director of research with Duchenne UK.

Research

Our research strategy has six elements to it, all of which are integral to accelerating and advancing research. Funding the research is the first crucial step. But on its own it isn't enough. We need to look at the overall landscape of research and drug development, and our strategy has been developed to reflect this.

1) Fund and accelerate research for early stage clinical trials

Our approach is 100% focused on advancing research and getting treatments into clinic and to patients as quickly as possible. Working alongside co-founder of Duchenne UK Emily Crossley, our co-founder, Alex Johnson, actively seeks out projects and potential therapies which could benefit the current generation of patients. We run an international grant call. We invest globally in basic science, translational research and clinical trials.

2) Facilitate and accelerate research

We are committed to accelerating the pace of research, ensuring that we remove potential obstacles and roadblocks that lie in the path of drug development. It is vital that the research we fund has the potential to translate into clinical trials, and so we fund the doctors, nurses and physiotherapists necessary to conduct trials in the UK. We created and expanded the DMD Hub which has the ambition that every child born with Duchenne in the UK has the opportunity to take part in research. We also support and encourage national and international collaboration to allow researchers and clinicians to collaborate and progress research. We are proud to support the Treat-NMD network and their bi-annual TACT meetings to review potential clinical trials for Duchenne muscular dystrophy.

3) Implementation of the Standards of Care (SoC) in the UK

The updated SoC were published in The Lancet of Neurology in 2018. They are ambitious and significantly advance on the 2010 version. While this is welcomed by families and clinicians, it presents challenges at a national level where the health care systems need to increase or change provision, and in many cases increase resources in order to deliver the fully updated SoC. We have launched a new project DMD Care UK to tackle this issue. The project will ensure everyone in the UK living with Duchenne has access to the best care.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

4) Work alongside industry

We work with industry, advising on clinical trial designs. We have advised on the protocols of a number of different trials. We work with Project Hercules and their industry partners to help collect the data they need to aid reimbursement decisions of drugs.

5) Continued engagement with regulators and policy makers

We are engaging with policy makers and regulators on many issues, from campaigning for Early Access to Medicines to engaging with the Health Technology Appraisal system.

6) Collaborate with families and charities globally

We work with families to empower them to get the best access to care and treatments for their children. As a result of COVID-19 we could not hold our free patient information days. We decided to work with Duchenne UK to hold 14 free patient information webinars that have been watched by 300 people. Alex Johnson sits on the board of the World Duchenne Organization to ensure we collaborate with charities internationally.

Our shared Scientific Advisory Board with Duchenne UK is

Professor Dame Kay Davies
Dr Mike Gait
Professor Annemeike Aartsma-Rus
Dr Tony Hall
Dr Eric Hoffman
Dr Bob McDonald
Alastair Robertson

Volunteers

The charity has an incredible ever-growing army of volunteers who enable the staging of the three main flagship fundraising multi-participant events.

An existing database of more than 100 names alongside local running and cycling clubs and Army Cadets, are called upon to help with pre-event preparation (goodie bag packing and race/ride packs) and on the day to hand out medals, water, refreshments marshal routes and support runners/riders at the start and finish.

Although in smaller numbers due to COVID measures, our volunteers have continued to do this when events returned in the second half of 2021.

Achievement and performance

Fundraising activities

Run Wigan Festival 2020

2017 saw us launch two new flagship fundraising events the first of which was the Run Wigan Festival in March featuring a Half Marathon, a 5k and Family Mile run. The event celebrated its third year in 2019 and, after the disappointment of the 2018 Half Marathon cancellation due to weather conditions and runner safety, and a fall in registered runners for the Main Race, a fourth distance was introduced to the event in the shape of a 10 Miler. The race was a sell-out.

The 4th Run Wigan Festival was due to take place on March 22, 2020, once again under the title sponsorship of HW Moon Toyota Wigan but with less than a week to go, the event was postponed at the start of the first National Lockdown. After first being rescheduled to take place alongside the Wigan 10k in September 2020, a second postponement was later confirmed until 2021. The event was eventually cancelled due to the ongoing restrictions and a third national Lockdown. The 2020 event was staged virtually with runners offered the chance to take part virtually and have their medals posted out or defer their place to 2021. We had a fantastic response with 1,500 runners taking part virtually and the event managed to raise just over £28,000.

The 2021 event was eventually cancelled due to the ongoing restrictions and a third national Lockdown. Given the likelihood that no mass participation events would take place until at least the second quarter of 2021, we made the decision to stage another Virtual Event - The Joining Jack 13 for 13.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

The Joining Jack 13 for 13

This was announced in January 2021 with runners invited to complete a virtual half marathon - 13.1 miles either on the official race route or a route/route of their choice throughout March. It was open to all ages to keep the event inclusive and for all Team JJ supporters to mark the 13th birthday of the charity's inspiration Jack Johnson in January 2021.

Runners submitted their evidence via email and received a bespoke medal. With extensive coverage across our social media channels and a concentrated marketing campaign to our Run Wigan Festival database, the event raised £6,500.

The date has been set for the return of the Run Wigan Festival in 2022 on Sunday, March 20, and registration is open.

*PLEASE NOTE 329 runners have deferred places in the 2022 event, and all runners from the virtual event were offered a 25% discount to sign up as a gesture of goodwill by the charity for their support and to maintain interaction with our established event network. This will have a major effect on fundraising from the event but it will be the final event to be affected financially by postponements and the fallout from COVID and lockdowns.

Wigan Bike Ride 2020

After three years of taking part as a team in organised Bike Rides, the charity made the decision to stage its first ever organised bike ride. This took place on July 22nd 2017 under the Title Sponsorship of Develop UK and featured a 50 Mile main ride on open roads through Wigan and Lancashire, and a 5 Mile family ride on closed roads along the Wigan 10k route. It was an unprecedented success and on Sunday, June 30, 2019, the charity staged the third Wigan Bike Ride and raised a record-breaking total.

The Bike Ride has now raised more than £95,000 and the date for the 4th event was set for July 5, 2020 but was cancelled due to the ongoing pandemic. The 4th Wigan Bike Ride did take place as a virtual event with 278 riders participating with support from all over the north-west and UK and from across the world including Australia, America, Chile and the UAE. Riders completed their 50 miles and were sent a Joining Jack JJ the Duchenne Destroyer medal and special edition Virtual Wigan Bike Ride T-shirt. The event raised more than £10,000.

Some light at the end of the tunnel saw the charity plan its first mass participation flagship event with the return of the 5th Wigan Bike Ride on Saturday, July 10, 2021. A change of venue due to availability and slightly smaller numbers (just under 300), saw the event take place just before COVID guidelines were fully relaxed so social distancing was maintained outdoors. New Hardcore and Highway routes were introduced for the 50 mile ride with £17,000 raised - we have now raised over £120,000 from the Bike Ride as a flagship event.

*PLEASE NOTE: As a gesture of goodwill, the remaining 51 riders who had registered to take part in 2020 before the decision to stage virtually was announced, and went on to complete the Virtual Ride, were offered a 50% discount to sign up in 2021. Along with smaller numbers, this did have an effect on fundraising.

The date has now been set for the 6th Wigan Bike Ride on Sunday, June 19, 2022 and registration is open.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

Wigan 10k 2020

On September 1st 2019, we completed our 7th Wigan 10k under a new title sponsor Williams BMW Bolton. First launched in 2013 as Joining Jack's FIRST flagship fundraising event, the race was another amazing day for the charity. More than 2,800 runners registered for the 10k and 500 for the Family Mile with more than £35,000 raised from runners' registration fees, sponsorship of the event, race registration fees, donations and merchandise sold. This was a slight fall on previous years with the added costs of a new title sponsor's branding adding to outgoings. When approached to continue the Title sponsorship, Williams BMW declined and the event was temporarily left without a main sponsor.

The 2020 Wigan 10k was earmarked for Sunday September 6. This was temporarily brought forward to Saturday, September 5th when the decision was taken to reschedule the Run Wigan Festival due to COVID-19, to run alongside the event over a complete weekend. The event would be sponsored by HW Moon Toyota Wigan as part of the sponsorship deal of the Run Wigan Festival.

However, with restrictions still in place surrounding mass participation events, the decision was taken to stage the 2020 8th Wigan 10k virtually. Runners were offered the option to defer their place to 2021 or take part in the virtual run - to be completed throughout September and October, and receive a bespoke Wigan 10k medal. Registration for virtual entries was reopened and a total of 537 runners completed the virtual run. The event raised £11,000 - again significantly down on previous years but still a profit in uncertain times.

The 9th Wigan 10k, featuring a 10k, 5k and Family Mile took place on Sunday, September 6th with almost 2,500 runners taking part. (NB, the 5k was rescheduled to take place on the Sunday after originally being planned for the Saturday evening.)

The event raised £21,000 and also saw the 20,000th runner cross the finish line since the event was launched in 2013. Numbers were a little disappointing but not unexpected and nevertheless encouraging as the events and fundraising industry continues to recover from COVID.

The date for next year's 10th Wigan 10 has been set for Sunday, September 11, 2022.

*PLEASE NOTE: The 268 runners who had registered to take part in 2020 before the decision to stage virtually was announced, were offered a 50% discount to sign up for 2021 as a gesture of goodwill.

Emirates Dubai Sevens

The 2020 event was cancelled due to the global pandemic.

The charity did look to take part in the 2021 and paid an agreed 20% of the registrations fees but, with concerns over players being able to travel from other countries, an enquiry was made into switching to the Over 45s category which could accommodate UK-based players who are more known to the Johnson family. However, this proved impractical as the category already had the allotted number of entries.

Alex, Andy and the Trustees will discuss entry into the 2022 early next year.

Yorkshire Three Peaks, Supporter Fundraising & Community Fundraising events

The biggest ever JJY3 Peaks had been planned for Saturday, September 6, 2020. This was also cancelled due to the global pandemic. The date has been set for the return of the JJY3P 2022 - the Joining Jack Yorkshire Three Peaks challenge - which will take place on Saturday, May 7. Recruitment will begin early in the New Year.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

Other events and fundraising

The charity relies heavily on our own flagship events and supporters taking part in mass participation events. Many if not all of these were cancelled in 2020 and in the first half of 2021 due to COVID-19 Coronavirus. This has had a significant effect on the charity's income both in 2020 and 2021 and has also affected overall fundraising income in 2021 with a continued knock-on effect of deferrals and discounted entries in the Run Wigan Festival 2022

The virtual 13 for 13 event and the return of both the Wigan Bike Ride and Wigan 10k, has raised home-based events have raised a combined £44,500 and there have been other smaller contributions from supporters and donors throughout the year.

The Emirates Dubai Sevens has previously raised £90,000 - £100,000 which has meant a significant reduction in fundraising for both 2020 and 2021.

Other fundraising initiatives 2021

The Joining Jack team have been working on a Team JJ merchandise campaign through the charity's eBay shop and also a Team JJ advent calendar to build awareness.

The charity has also had continued support from sponsors, event partners and supporters throughout the continued restrictions and limited fundraising opportunities, maintaining a strong connection with the Team JJ brand and continuing to raise awareness of our overall charitable objective.

Achievement and performance

This year's advocacy activities

We continued to represent the Duchenne community by speaking at virtually at international patient conferences around the world, workshops and meetings with the FDA, EMA, MHRA, NICE and at the Houses of Parliament.

Ensuring the best care for all patients - DMD Care UK. It is our mission that every child with Duchenne - wherever they live in the UK - should be able to access the same quality of care, and that that level of care should be excellent. We don't want people to "make do", we want them to shine.

We have brought together the DMD community of patients and families with neuromuscular experts, and specialist clinicians to try to make this a reality with our DMD Care UK project.

"DMD Care UK is such an important project for raising and harmonising standards of care for ALL people in the UK living with DMD. It works because we are a collaboration between neuromuscular expert centres, specialist clinicians and the patient community - we are all working towards the same goal!" Dr Michela Guglieri, John Walton Muscular Dystrophy Research Centre in Newcastle; PI of DMD Care UK

We have been carrying out a comprehensive review to get a benchmark of how five areas are managed across the country.

- Psychosocial
- Bone and Endocrine Health
- Cardiac Health
- Respiratory Health
- Physiotherapy
- Emergency Care

Next year we will begin work on the other 5 areas of care we have identified as priorities.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

Update on Psychosocial Care:

This year one of our key focuses has been psychosocial care, looking at the mental health of people with DMD and their families. We are partnering with the Duchenne Research Fund to look at research into psychosocial care and research. We want every patient and their family members to receive the appropriate psychosocial evaluation, care and treatment throughout their lives.

Update on Bone and Endocrine health:

The Endocrine system is a network of glands in the body which make the hormones that help us all function. We are working with the British Society of Paediatric Endocrinology and Diabetes to find an effective way to monitor the health of the endocrine system, and also bone health. Steroids have a noticeable effect on these areas so we are producing guidance for families and health professionals.

One particularly challenging area is delayed puberty so we have produced leaflets specifically on this subject giving help and advice.

We have also produced detailed advice on steroid stress dosing - when extra steroids are need for patients who become ill or injured. We are working on updating checklists in clinics across the country to educate parents and medical staff about this. We've also produced a wristband to be worn by people on steroids so that medical staff in Accident and Emergency departments are alerted and know that they need special treatment. So far 340 bracelets have been ordered by families.

Educating parents is key so this year we held a webinar on steroid stress dosing. This was well attended.

Update on Emergency Care:

We are also developing an emergency care app, which is currently in the testing phase.

Update on Cardiac Health:

We have developed new recommendations due to be published in Q1 2022.

Achievement and performance

Update on Respiratory Health:

We have developed new recommendations due to be published in Q1 2022.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

The DMD Hub - expending access to clinical trials:

We are so proud of the pioneering work of the DMD Hub. We want to make it possible for any family to take part in clinical trials if they want to, allowing them to access treatments they wouldn't otherwise receive.

In 2015, when we created the concept of the DMD Hub there just weren't the facilities to make this happen. Each year, we extend our outposts and staff to make this a reality. Thanks to the DMD Hub, 300 more boys have been recruited onto clinical trials so far. 11 Hospitals are now running 10 trials into potential treatments for DMD.

We have extended the contract for the DMD Hub Manager, Emma Heslop, for another four years. She is the vital contact point between clinicians, industry partners and patients. She helps select sites and recruit patients and makes sure best practice is shared between Hub sites.

We have expanded the DMD Hub team to look at improving the recruitment of patients to trials, and the training of Hub staff to prepare for more gene therapy trials in the UK.

Through our seed funding the DMD Hub has been able to fund five new posts across the different Hub sites, employing people like research nurses and physiotherapists to help run clinical trials.

The DMD Hub is collaborating on an international patient preference project with PPMD and RTI International. This project will assess and explore clinician, patient, and caregiver attitudes, priorities, and risk tolerance regarding gene therapy as a potential treatment option for Duchenne muscular dystrophy. With gene therapies entering human studies, this is a critical time to understand the treatment preference of people affected by Duchenne. These technologies offer great promise to be disease modifying but come with risks and burden.

We have funded new gene therapy work to overcome immunological challenges that prevent gene therapy being available to be used to treat all patients.

First Patient dosed with gene therapy through DMD Hub network. We are planning a workshop

Partnership with Whizz Kidz and PPL to build the dream chair:

Williams Advanced Engineering, the technology spin off of Williams F1, have joined forces with Duchenne UK and Whizz-Kidz to input on the design of our dream wheelchair.

We made powerful links across the Duchenne Community: parents, scientists, clinicians and Governments to identify and fund the best treatments worldwide for Duchenne through our leadership and sponsorship of Treat NMD, a global network of scientists and clinicians.

Alex continues to sit on the board of the World Duchenne Organization (WDO) that has helped to organize international awareness events like World Duchenne Awareness Day and provides support to charities around the world.

We have continued to provide vital support to families during COVID. We have hosted educational webinars and held our first in person patient conference since the pandemic began in October in Manchester.

Alex has continued to provide support to families through telephone calls.

We have continued to hold online gaming tournaments for the Duchenne community. This has helped people living with Duchenne connect and create support networks to improve mental health.

Duchenne UK has recruited a new Director of Research and we have been working on a new research strategy to share in Q1 2022.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

Achievement and performance

Funding and research decisions

We have listed in the table below a list of the grants we have awarded to date. We have colour-coded the grants to show how we are supporting the whole therapeutic development pipeline. Joining Jack is committed to ensuring that as much as possible of our funds goes to developing research into a treatment or a cure for Duchenne Muscular Dystrophy.

We are particularly focused on transitional research, research that takes potential therapeutics out of laboratories and into clinical trials. Working closely with our partner charity Duchenne UK, our trusted team of scientific advisors, patient advisory board and trustees, we have made major decisions on how to spend the funds raised. The grants that we have awarded have led to breakthroughs that are changing the therapeutic landscape for the Duchenne community.

DMD Care UK = Red
Basic Research = Yellow
Preclinical Research = Green
Clinical Trial Support = Blue
Clinical Trials = Orange

Project Name	Research/Institution or Company	Project Status	Total Grant Award
Hydrotherapy Clinical Trial	Dr De Goede, Royal Preston Hospital	Started	£118,000
Immunology Grant Call Award	Professor Kanneboyina Nagaraju at Binghamton, the State University of New York	Started	£1,000
Biomarker Trial	Duke University	Started	£20,000
Dream Chair development	Whizz Kidz	ONGOING	£50,000
DMD Care UK	Newcastle University	ONGOING	£65,000
Immunology Grant	University of Florida	ONGOING	£185,000
Splint Trial	Newcastle University	Started	10,0000
Stem Cells	University of Minnesota	ONGOING	£140,000
Vitamin B3	Leiden University	Complete	£10,000
Tackling fibrosis and muscle regeneration	Agada Biosciences	Terminated	£25,000
Repurposing Drugs	Dr Olivier Dorchies University of Geneva	ONGOING	£25,000
Testosterone extension	Prof Volker Straub University of Newcastle	ONGOING	£10,000
Adult NMCCC	Dr Chiara Marini-Bettolo University of Newcastle	ONGOING	£10,000

Project Name	Research/Institution or Company	Project Status	Total Grant Award
<u>Open label extension study for Tamoxifen</u>	Dr Dirk Fischer University Children's Hospital Basel	ONGOING	£230,000
<u>Taurine</u>	Dr Peter Arthur, Senior Lecturer The University of Western Australia	COMPLETE 2018-2020	£50,000
<u>Fibrosis</u>	Dr Lee Borthwich, University of Newcastle	ONGOING 2018-2019	£10,000
<u>New ways of delivering Gene Therapy</u>	EVOX Therapeutics	TERMINATED	£200,000
<u>Understanding heart disease in DMD</u>	Dr John Bourke Freeman Hospital	ONGOING	£67,000
<u>Investigating soy products as a treatment for DMD</u>	Prof Steve Winder University of Sheffield	COMPLETE 2018-2019	£30,500
<u>Preclinical study of the combination of tamoxifen, L-citrulline and metformin</u>	Dr Olivier Dorchies University of Geneva	ONGOING 2018-2020	£200,000
<u>Use of Elastase Inhibitors to Treat DMD</u>	Dr Addolorata Pisconti University of Liverpool	COMPLETE 2017-2018	£36,365
<u>Duchenne Clinical Research Nurse</u>	Alder Hey Children's Hospital, Liverpool	ONGOING 2018-2020	£32,106.50
<u>F2 Neuromuscular Clinical Research Doctor</u>	Alder Hey Children's Hospital, Liverpool	COMPLETE 2017-2018	£30,513
<u>ST4 Neuromuscular Clinical Research Doctor</u>	Alder Hey Children's Hospital, Liverpool	COMPLETE 2017-2019	£127,121
<u>Tamoxifen Clinical Trial</u>	Dr Dirk Fischer University Children's Hospital Basel	ONGOING	£194,996.99
<u>Tamoxifen Project Manager</u>	Dr Dirk Fischer University Children's Hospital Basel	ONGOING	£97,000
<u>TREAT-NMD DMD Co-Ordinator Role</u>	University of Newcastle	COMPLETE 2015-2020	£78,832.66
<u>Physiotherapist</u>	Alder Hey Children's Hospital, Liverpool	COMPLETE 2016-2018	£45,960
<u>Duchenne Clinical Trial Nurse</u>	Royal Victoria Infirmary, Newcastle	COMPLETE 2017-2018	£22,500
<u>Co-Funded Lectureship for a Clinical Research Lectureship/ Senior Lectureship in Duchenne Muscular Dystrophy</u>	Dr Guglieri University of Newcastle	COMPLETE 2015-2020	£35,714.30
<u>Assessing the preclinical therapeutic impact of cannabidiol for DMD</u>	Dr Keith Foster The University of Reading	COMPLETE 2014-2016	£6213.09
<u>The Duchenne Forum</u>	Muscular Dystrophy Campaign	COMPLETE 2014-2017	£55,346
<u>Supporting 8 basic research projects</u>			

Project Name	Research/Institution or Company	Project Status	Total Grant Award
Gene therapy	Solid GT	COMPLETE	\$1,666,666.66
VBP-15	Boston, USA	2014-2016	
Phase I Clinical Trial	Reveragen BioPharma Inc, USA	COMPLETE	\$400,000
DMD Heart Protection Study	Dr Spinty	COMPLETE	£14,000
Phase I/2	Alder Hey	2014-2017	
Clinical trial of HT-100	Akashi Therapeutics	COMPLETE	\$100,000
	USA	2013-2015	
Developing biomarkers for Utrophin Modulators	Summit Corporation	COMPLETE	£100,000
	Oxford, UK	2013-2015	

Financial review

Financial position

Results for the year are shown in the Statement of Financial Activities on page 14.

Investment policy and objectives

The charity's investment policy is to retain all available funds on deposit to give sufficient liquidity to meet ongoing day-to-day needs.

Reserves policy

The Trustees have determined that a minimum unrestricted reserve of approximately £10,000 is required to ensure the ongoing operations of the charity. The charity does not require a significant restricted reserve because it does not currently have material fixed costs. The charity recognises it may be appropriate to allow the reserve to fluctuate as a result of short-term cash inflows and outflows and to ensure the funding of projects to which it is contractually committed.

Future plans

Our future plans

In the coming year we plan to:

- Through DMD Care UK continue to implement the new Standards of Care for patients in the UK.
- Provide education to families on research and care.
- Provide psychological support to families and patients living with Duchenne through the pathway we develop.
- Continue to develop the Duchenne Hub.
- Create research opportunities for Adults with Duchenne by developing new outcome measures.
- Work to overcome the immunological issues preventing delivery of gene therapy.
- Advance research into the methods of delivery of gene therapy for Duchenne patients.
- Bring the Dream Chair to market.
- Develop new outcome measures for clinical trials.
- Help optimise clinical trial designs

Structure, governance and management

Constitution

The charity is governed by its Declaration of Trust dated 28 February 2012, as amended by Deed dated 16 July 2012.

Recruitment and appointment of new trustees

The trustees who have served during the year are set out on page 1. The trustees are appointed by the committee.

JOINING JACK

REPORT OF THE TRUSTEES FOR THE YEAR ENDED 30 APRIL 2021

Structure, governance and management

Organisational structure

The trustees meet on a regular basis to discuss the work and development of the organisation. The Scientific Advisory Board reviews applications for funding received from the pharmaceuticals sector and reports its findings back to the Board of Trustees.

Induction and training of new trustees

New trustees are given guidance provided by the committee which covers such items as roles and responsibilities, legal obligations under charity law, organisational structures and decision-making processes, business planning and understanding financial information. The induction process also involves new trustees meeting key employees and other trustees. Trustees are encouraged to attend appropriate training events which will facilitate their understanding of their role and meet their individual training needs.

Statement of trustees' responsibilities


The trustees are responsible for preparing the Report of the Trustees and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales, the Charities Act 2011, Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including the income and expenditure, of the charity for that period. In preparing those financial statements, the trustees are required to

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charity SORP;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in business.

The trustees are responsible for keeping proper accounting records which disclose with reasonable accuracy at any time the financial position of the charity and to enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the trust deed. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Approved by order of the board of trustees on 10th February 2022 and signed on its behalf by:



Mr K Radlinski - Trustee

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF JOINING JACK

Opinion

We have audited the financial statements of Joining Jack (the 'charity') for the year ended 30 April 2021 which comprise the Statement of Financial Activities, the Balance Sheet, the Cash Flow Statement and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 30 April 2021 and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the trustees with respect to going concern are described in the relevant sections of this report.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters where the Charities (Accounts and Reports) Regulations 2008 requires us to report to you if, in our opinion:

- the information given in the Report of the Trustees is inconsistent in any material respect with the financial statements; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records and returns; or
- we have not received all the information and explanations we require for our audit.

REPORT OF THE INDEPENDENT AUDITORS TO THE TRUSTEES OF JOINING JACK

Responsibilities of trustees

As explained more fully in the Statement of Trustees' Responsibilities, the trustees are responsible for the preparation of the financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Our responsibilities for the audit of the financial statements

We have been appointed as auditors under Section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue a Report of the Independent Auditors that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

We identified areas of laws and regulations that could reasonably be expected to have a material effect on the financial statements from our general commercial and sector experience, through discussion with the directors and other management (as required by auditing standards), and from inspection of the charity's regulatory and legal correspondence and discussed with the directors and other management the policies and procedures regarding compliance with laws and regulations. We communicated identified laws and regulations throughout our team and remained alert to any indications of non-compliance throughout the audit.

The potential effect of these laws and regulations on the financial statements varies considerably.

Firstly, the charity is subject to laws and regulations that directly affect the financial statements including financial reporting legislation (including related companies legislation), distributable profits legislation, pensions legislation and taxation legislation, and we assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.

Owing to the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our Report of the Independent Auditors.

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.



.....
Paul G Farrington BSc (Hons) ACA (Senior Statutory Auditor)
For and on behalf of NR Barton
1st Floor Waterside House
Waterside Drive
Wigan
Lancashire
WN3 5AZ

Date: 10/02/2022

JOINING JACK

STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 30 APRIL 2021

		30.4.21 Unrestricted fund £	30.4.20 Total funds £
INCOME AND ENDOWMENTS FROM	Notes		
Donations and legacies	2	44,590	151,844
Other trading activities	3	142,423	217,852
Investment income	4	<u>155</u>	<u>586</u>
Total		187,168	370,282
 EXPENDITURE ON			
Raising funds	5	68,323	152,992
Charitable activities	6		
Funding research		434,323	335,328
Other		<u>(277,073)</u>	<u>747,312</u>
Total		<u>225,573</u>	<u>1,235,632</u>
 NET INCOME/(EXPENDITURE)		(38,405)	(865,350)
 RECONCILIATION OF FUNDS			
Total funds brought forward		<u>2,993,539</u>	<u>3,858,889</u>
 TOTAL FUNDS CARRIED FORWARD		<u><u>2,955,134</u></u>	<u><u>2,993,539</u></u>

The notes form part of these financial statements

JOINING JACK

BALANCE SHEET 30 APRIL 2021

	Notes	30.4.21 Unrestricted fund £	30.4.20 Total funds £
FIXED ASSETS			
Tangible assets	12	255	318
Social investments	13	<u>592,260</u>	<u>315,187</u>
		592,515	315,505
CURRENT ASSETS			
Stocks	14	322	322
Debtors	15	85	85
Cash at bank		<u>2,367,631</u>	<u>2,686,183</u>
		2,368,038	2,686,590
CREDITORS			
Amounts falling due within one year	16	(5,419)	(8,556)
NET CURRENT ASSETS		<u>2,362,619</u>	<u>2,678,034</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>2,955,134</u>	<u>2,993,539</u>
NET ASSETS		<u>2,955,134</u>	<u>2,993,539</u>
FUNDS	17		
Unrestricted funds		<u>2,955,134</u>	<u>2,993,539</u>
TOTAL FUNDS		<u>2,955,134</u>	<u>2,993,539</u>

The financial statements were approved by the Board of Trustees and authorised for issue on 10 February 2022 and were signed on its behalf by:



Mr J Whitworth - Trustee

JOINING JACK

CASH FLOW STATEMENT FOR THE YEAR ENDED 30 APRIL 2021

	Notes	30.4.21 £	30.4.20 £
Cash flows from operating activities			
Cash generated from operations	1	<u>(318,706)</u>	<u>(119,869)</u>
Net cash used in operating activities		<u>(41,633)</u>	<u>(119,869)</u>
Cash flows from investing activities			
Interest received		155	586
Dividends received		<u>-</u>	<u>256,918</u>
Net cash provided by investing activities		<u>155</u>	<u>257,504</u>
		<u> </u>	<u> </u>
Change in cash and cash equivalents in the reporting period		(318,552)	137,635
Cash and cash equivalents at the beginning of the reporting period		<u>2,686,183</u>	<u>2,548,548</u>
Cash and cash equivalents at the end of the reporting period		<u><u>2,367,631</u></u>	<u><u>2,686,183</u></u>

The notes form part of these financial statements

JOINING JACK

NOTES TO THE CASH FLOW STATEMENT FOR THE YEAR ENDED 30 APRIL 2021

1. RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES

	30.4.21 £	30.4.20 £
Net expenditure for the reporting period (as per the Statement of Financial Activities)	(38,405)	(865,350)
Adjustments for:		
Depreciation charges	64	80
Losses/(gain) on investments	(277,073)	1,000,816
Interest received	(155)	(586)
Dividends received	-	(256,918)
Decrease in stocks	-	8
(Decrease)/increase in creditors	<u>(3,137)</u>	<u>2,081</u>
Net cash used in operations	<u>(318,706)</u>	<u>(119,869)</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.5.20 £	Cash flow £	At 30.4.21 £
Net cash			
Cash at bank	<u>2,686,183</u>	<u>(318,552)</u>	<u>2,367,631</u>
	<u>2,686,183</u>	<u>(318,552)</u>	<u>2,367,631</u>
Total	<u>2,686,183</u>	<u>(318,552)</u>	<u>2,367,631</u>

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 APRIL 2021

1. ACCOUNTING POLICIES

Basis of preparing the financial statements

The financial statements of the charity, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Charities Act 2011. The financial statements have been prepared under the historical cost convention.

Income

All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

Tangible fixed assets

Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

Fixtures and fittings	- 20% on reducing balance
-----------------------	---------------------------

Social investments

Social investments comprise programme related investments which are measured at cost less impairment.

Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation

The charity is exempt from tax on its charitable activities.

Fund accounting

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2021

2. DONATIONS AND LEGACIES

	30.4.21	30.4.20
	£	£
Donations	<u>44,590</u>	<u>151,844</u>

3. OTHER TRADING ACTIVITIES

	30.4.21	30.4.20
	£	£
Fundraising events	142,423	217,672
Merchandise sales	<u>-</u>	<u>180</u>
	<u>142,423</u>	<u>217,852</u>

4. INVESTMENT INCOME

	30.4.21	30.4.20
	£	£
Deposit account interest	<u>155</u>	<u>586</u>

5. RAISING FUNDS

Raising donations and legacies

	30.4.21	30.4.20
	£	£
Staff costs	53,725	51,935
Rent	2,400	2,400
Fundraising costs	17,762	5,169
Travel costs	-	3,142
Postage, stationery and sundry	864	1,619
Computer costs	1,986	1,572
Depreciation	64	80
Government Grants	(12,197)	-
Support costs	<u>4,630</u>	<u>-</u>
	<u>69,234</u>	<u>65,917</u>

6. CHARITABLE ACTIVITIES COSTS

	Grant funding of activities (see note 7) £
Funding research	<u>434,323</u>

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2021

7. GRANTS PAYABLE

	30.4.21	30.4.20
	£	£
Funding research	<u>434,323</u>	<u>335,328</u>

The total grants paid to institutions during the year was as follows:

	30.4.21	30.4.20
	£	£
Newcastle University	-	15,328
Duchenne UK Grant Call	434,323	200,000
Catabasis	-	100,000
Testosterone	-	10,000
Adult Hub	<u>-</u>	<u>10,000</u>
	<u>434,323</u>	<u>335,328</u>

8. SUPPORT COSTS

	Governance costs
	£
Raising donations and legacies	<u>4,630</u>

Support costs, included in the above, are as follows:

	30.4.21	30.4.20
	Raising donations and legacies	Total activities
	£	£
Auditors' remuneration	4,090	3,414
Auditors' remuneration for non audit work	360	-
Accountancy and legal fees	<u>180</u>	<u>-</u>
	<u>4,630</u>	<u>3,414</u>

9. AUDITORS' REMUNERATION

	30.4.21	30.4.20
	£	£
Fees payable to the charity's auditors for the audit of the charity's financial statements	4,090	3,414
Auditors' remuneration for non audit work	<u>360</u>	<u>-</u>

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2021

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 30 April 2021 nor for the year ended 30 April 2020.

Trustees' expenses

There were no trustees' expenses paid for the year ended 30 April 2021 nor for the year ended 30 April 2020.

11. STAFF COSTS

	30.4.21	30.4.20
	£	£
Wages and salaries	<u>53,725</u>	<u>51,935</u>
	<u>53,725</u>	<u>51,935</u>

The average monthly number of employees during the year was as follows:

	30.4.21	30.4.20
Costs of generating voluntary income	2	2
Research and campaigning	<u>1</u>	<u>1</u>
	<u>3</u>	<u>3</u>

No employees received emoluments in excess of £60,000.

12. TANGIBLE FIXED ASSETS

	Fixtures and fittings £
COST	
At 1 May 2020 and 30 April 2021	<u>1,461</u>
DEPRECIATION	
At 1 May 2020	1,143
Charge for year	<u>63</u>
At 30 April 2021	<u>1,206</u>
NET BOOK VALUE	
At 30 April 2021	<u>255</u>
At 30 April 2020	<u>318</u>

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2021

13. SOCIAL INVESTMENTS

Joining Jack is a shareholder in Duchenne Research (UK) Investment Ltd [DRIL], a company incorporated in the UK as a company limited by shares on 9 December 2014.

Alex Johnson, one of the founders of Joining Jack, is a director of DRIL.

The purpose of DRIL is to invest in SOLID Biosciences. SOLID Biosciences undertakes gene therapy-based research into Duchenne Muscular Dystrophy and drug development and treatments in connection therewith. SOLID Biosciences is listed on Nasdaq.

At 30 April 2021 the share price of SOLID Biosciences had reduced as a result of research projects led by the company being put on hold given the implications the global pandemic. As a result, the market value of the investment in DRIL as at the balance sheet date is shows a revaluation of £277,073 (2020 - £743,898 impairment) compared to the original cost of £1,073,399.

Further commentary regarding the charity's investment in DRIL is included in the financial review section of the Trustee's Report.

14. STOCKS

	30.4.21	30.4.20
	£	£
Stocks	<u>322</u>	<u>322</u>

15. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	30.4.21	30.4.20
	£	£
Gift Aid debtor	<u>85</u>	<u>85</u>

16. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	30.4.21	30.4.20
	£	£
Trade creditors	1,999	2,000
Taxation and social security	-	708
Other creditors	<u>3,420</u>	<u>5,848</u>
	<u>5,419</u>	<u>8,556</u>

17. MOVEMENT IN FUNDS

	At 1.5.20	Net movement in funds	At 30.4.21
	£	£	£
Unrestricted funds			
General fund	2,993,539	(38,405)	2,955,134
	<u>2,993,539</u>	<u>(38,405)</u>	<u>2,955,134</u>
TOTAL FUNDS			
	<u>2,993,539</u>	<u>(38,405)</u>	<u>2,955,134</u>

JOINING JACK

NOTES TO THE FINANCIAL STATEMENTS - continued FOR THE YEAR ENDED 30 APRIL 2021

17. MOVEMENT IN FUNDS - continued

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	187,168	(225,573)	(38,405)
TOTAL FUNDS	<u>187,168</u>	<u>(225,573)</u>	<u>(38,405)</u>

Comparatives for movement in funds

	At 1.5.19 £	Net movement in funds £	At 30.4.20 £
Unrestricted funds			
General fund	3,858,889	(865,350)	2,993,539
TOTAL FUNDS	<u>3,858,889</u>	<u>(865,350)</u>	<u>2,993,539</u>

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	370,282	(1,235,632)	(865,350)
TOTAL FUNDS	<u>370,282</u>	<u>(1,235,632)</u>	<u>(865,350)</u>

A current year 12 months and prior year 12 months combined position is as follows:

	At 1.5.19 £	Net movement in funds £	At 30.4.21 £
Unrestricted funds			
General fund	3,858,889	(903,755)	2,955,134
TOTAL FUNDS	<u>3,858,889</u>	<u>(903,755)</u>	<u>2,955,134</u>

JOINING JACK

**NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30 APRIL 2021**

17. MOVEMENT IN FUNDS - continued

A current year 12 months and prior year 12 months combined net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	557,450	(1,461,205)	(903,755)
TOTAL FUNDS	<u>557,450</u>	<u>(1,461,205)</u>	<u>(903,755)</u>

18. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 30 April 2021.

JOINING JACK

DETAILED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 30 APRIL 2021

	30.4.21 £	30.4.20 £
INCOME AND ENDOWMENTS		
Donations and legacies		
Donations	44,590	151,844
Other trading activities		
Fundraising events	142,423	217,672
Merchandise sales	-	180
	142,423	217,852
Investment income		
Deposit account interest	155	586
Total incoming resources	187,168	370,282
EXPENDITURE		
Raising donations and legacies		
Wages	53,725	51,935
Rent	2,400	2,400
Fundraising costs	17,762	5,169
Travel costs	-	3,142
Postage, stationery and sundry	864	1,619
Computer costs	1,986	1,572
Depreciation of fixtures and fittings	64	80
Government Grants	(12,197)	-
	64,604	65,917
Other trading activities		
Cost of events	(911)	87,075
Charitable activities		
Grants to institutions	434,323	335,328
Other		
Impairment losses for intangible fixed assets	(277,073)	743,898
Support costs		
Governance costs		
Auditors' remuneration	4,090	3,414
Auditors' remuneration for non-audit work	360	-
Accountancy and legal fees	180	-
	4,630	3,414
Total resources expended	225,573	1,235,632
Net expenditure	(38,405)	(865,350)

This page does not form part of the statutory financial statements

